UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   FORM N-CSR

              CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT

                              INVESTMENT COMPANIES

Investment Company Act file number  811-10325

                            VANECK VECTORS ETF TRUST
               (Exact name of registrant as specified in charter)

                      666 Third Avenue, New York, NY 10017
               (Address of principal executive offices) (Zip code)

                         Van Eck Associates Corporation
                      666 Third Avenue, New York, NY 10017
                     (Name and address of agent for service)

Registrant's telephone number, including area code: (212) 293-2000

Date of fiscal year end:  SEPTEMBER 30

Date of reporting period: MARCH 31, 2018

 

ITEM 1. REPORT TO SHAREHOLDERS

 

SEMI-ANNUAL REPORT

March 31, 2018

(unaudited)

 

 

VANECK VECTORS®  
   
Biotech ETF BBH
   
Environmental Services ETF EVX®
   
Gaming ETF BJK®
   
Generic Drugs ETF GNRX
   
Pharmaceutical ETF PPH®
   
Retail ETF RTH®
   
Semiconductor ETF SMH®

 

     
  800.826.2333 vaneck.com
 

 

 

President’s Letter 1
Management Discussion 3
Biotech ETF 3
Environmental Services ETF 3
Gaming ETF 4
Generic Drugs ETF 4
Pharmaceutical ETF 4
Retail ETF 4
Semiconductor ETF 5
Explanation of Expenses 6
Schedule of Investments  
Biotech ETF 7
Environmental Services ETF 9
Gaming ETF 11
Generic Drugs ETF 13
Pharmaceutical ETF 15
Retail ETF 17
Semiconductor ETF 18
Statements of Assets and Liabilities  
Biotech ETF 20
Environmental Services ETF 20
Gaming ETF 20
Generic Drugs ETF 20
Pharmaceutical ETF 21
Retail ETF 21
Semiconductor ETF 21
Statements of Operations  
Biotech ETF 22
Environmental Services ETF 22
Gaming ETF 22
Generic Drugs ETF 22
Pharmaceutical ETF 23
Retail ETF 23
Semiconductor ETF 23
Statements of Changes in Net Assets  
Biotech ETF 24
Environmental Services ETF 24
Gaming ETF 25
Generic Drugs ETF 25
Pharmaceutical ETF 25
Retail ETF 26
Semiconductor ETF 26
Financial Highlights  
Biotech ETF 27
Environmental Services ETF 27
Gaming ETF 28
Generic Drugs ETF 28
Pharmaceutical ETF 29
Retail ETF 29
Semiconductor ETF 30
Notes to Financial Statements 31

 

 

The information contained in the management discussion represents the opinions of VanEck Vectors ETFs and may differ from other persons. This information is not intended to be a forecast of future events, a guarantee of future results or investment advice. The information contained herein regarding each index has been provided by the relevant index provider. Also, unless otherwise specifically noted, any discussion of the Funds’ holdings and the Funds’ performance, and the views of VanEck Vectors ETFs are as of March 31, 2018, and are subject to change.

 

VANECK VECTORS ETFs

March 31, 2018 (unaudited)

 

Dear Shareholder:

 

We are pleased to present this semi-annual report for the seven industry exchange-traded funds (ETFs) of the VanEck Vectors® ETF Trust for the six-month period ended March 31, 2018.

 

One of the two top performing funds in our suite of industry ETFs was the VanEck Vectors Semiconductor ETF (NYSE Arca: SMH) which returned 13.36% for the period under review.

 

The semiconductor industry ended 2017 on a high: global sales for 2017 of $412.2 billion were 21.6% higher than those in 2016. In addition, sales for December 2017 ($38.0 billion) and the fourth quarter 2017 ($114.0 billion) were the highest monthly and quarterly sales respectively ever recorded.1 According to John Neuffer, president and CEO of the Semiconductor Industry Association, “[a]s semiconductors have become more heavily embedded in an ever-increasing number of products—from cars to coffee makers—and nascent technologies like artificial intelligence, virtual reality, and the Internet of Things have emerged, global demand for semiconductors has increased, leading to landmark sales in 2017 and a bright outlook for the long term.”2

 

The industry started 2018 on a solid footing. In January, sales were up 22.7% compared to January 2017 and the market grew year over year for the eighteenth consecutive month.3 Sales in February were also solid, up 21% compared to February 2017. Fourth quarter earnings from several of the large chipmakers, reported in the first quarter of 2017,4 were particularly solid, with the vast majority of reporting companies in SMH portfolio beating earnings expectations.

 

Semiconductors – Worldwide Market Billings: 3-Month Moving Averages ($bn)

 

 

Source: Semiconductor Industry Association. Data as of January 31, 2018. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue. Past performance is no guarantee of future results; current performance may be lower or higher than the performance data quoted.

 

Access investment and market insights from VanEck’s investment professionals by subscribing to our blogs. To subscribe to the updates, please contact us at 800.826.2333 or visit vaneck.com/subscription to register.

1

VANECK VECTORS ETFs

(unaudited) (continued)

 

Thank you for participating in the VanEck Vectors ETF Trust. On the following pages, you will find the performance record of each of the funds for the six months ended March 31, 2018. You will also find their financial statements. We value your continuing confidence in us and look forward to helping you meet your investment goals in future.

 

 

Jan F. van Eck

Trustee and President

VanEck Vectors ETF Trust

 

April 16, 2018

 

Represents the opinions of the investment adviser. Past performance is no guarantee of future results. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.

 

1 Semiconductor Industry Association: Annual Semiconductor Sales Increase 21.6 Percent, Top $400 Billion for First Time, https://www.semiconductors.org/news/2018/02/05/global_sales_report_2017/annual_semiconductor_sales_increase_21.6_percent_top_ 400_billion_for_first_time/
   
2 Ibid.
   
3 Semiconductor Industry Association: January Semiconductor Sales Up 22.7 Percent Compared to Last Year, https://www.semiconductors.org/news/2018/03/05/global_sales_report_2017/january_semiconductor_sales_up_22.7_percent_compared_ to_last_year/
   
4 Semiconductor Industry Association: Global Semiconductor Sales Up 21 Percent Year-to-Year in February, https://www.semiconductors.org/news/2018/04/02/global_sales_report_2017/global_semiconductor_sales_up_21_percent_year_to_year_ in_february/
2

 

 

Management Discussion (unaudited)

 

Four of the seven VanEck Vectors Industry ETFs realized positive performance in the six months ended March 31, 2018. The two best performers were VanEck Vectors Retail ETF (NYSE Arca: RTH), posting a total return of 16.26%, and VanEck Vectors Semiconductor ETF (NYSE Arca: SMH), in second place, providing a total return of 13.36%.

 

 

 

Source: VanEck. Returns based on NAV. The performance data quoted represent past performance. Past performance is not a guarantee of future results. Performance information for the Funds reflects temporary waivers of expenses and/or fees. Had the Funds incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Funds will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than performance data quoted.

 

Biotech – Not helped by State of the Union address

 

Biotech stocks failed to perform well over the six-month period. Following highs through mid-October, biotech stocks subsequently fell over the next three months to end 2017 down on the quarter. Despite some recovery through the end of January, stocks were not helped by President Trump’s mention of “fixing the injustice” of the high prices of U.S. drugs in his State of the Union address,1 nor the announcement of a prospective joint health care venture between Amazon.com, Berkshire Hathaway, and JPMorgan Chase & Co.2 The selloff at the end of the month and into the first week of February saw biotech stocks plummet. The recovery thereafter through the end of the reporting period on March 31, 2018 was minimal.

 

Positive contributions to the Fund’s performance came mainly from three companies: Illumina, Neurocrine Biosciences, and Vertex Pharmaceuticals (4.6%, 2.0%, and 5.0% of Fund net assets respectively). The companies that detracted most from performance were Celgene, Incyte, and Regeneron Pharmaceuticals (7.3%, 4.2%, and 4.8% of Fund net assets, respectively).

 

Environmental Services – No lasting benefit in 2018 from 2017 hurricanes

 

Following the steep improvement in their performance in both August and September 2017 (on the back of the three hurricanes that had hit the U.S. and its territories in the Caribbean), environmental services stocks essentially moved sideways thereafter, with a number of ups and downs, ending the six-month period under review down slightly.

 

While large- and small-cap stocks provided positive total returns, their contribution was outweighed by the negative total returns of the Fund’s mid-cap companies. Waste Management (10.0% of Fund net assets), Cantel Medical (3.9% of Fund net assets), and STERIS (10.2% of Fund net assets) were the top three contributors to positive total returns. CECO Environmental (1.9% of Fund net assets), Stericycle (3.8% of Fund net assets), and ABM Industries (3.9% of Fund net assets) detracted the most from performance.

3

VANECK VECTORS ETFs

(unaudited) (continued)

 

Gaming – Macau powers ahead

 

The Fund posted a rise of 10.89% for the six-month period. The fourth quarter of 2017 was strong with gaming stocks on an upward trajectory through the end of the year. In Macau, China—the world’s biggest gaming hub—the improvement in the gaming industry’s fortunes over the final three months of 2017 was impressive. In each of these months the gross revenue from “Games of Fortune” (as the Macau authorities3 describe them) was higher than that recorded in the same month in the prior year. In October, November, and December 2017, they were 22.1%, 22.6%, and 14.6%, respectively, higher than in the same months in 2016.4 2018 started strongly, with revenues in January, February, and March up 36.4%, 5.7%, and 22.2%, respectively, over 2017.5 In Nevada, the narrative for the last quarter of 2017 and the start of 2018 was not as rosy. While the “gaming wins” in both October and December may have increased incrementally year over year, the “gaming win” for November decreased 2.3% compared with that in November 2016.6 While February 2018’s win may have been 7.68% up on that of February 2017, January’s was 2.05% down on that of January 2017.7

 

U.S. listed companies were the leading contributors to performance, followed by those listed in China (Hong Kong). The other major contributors were companies in Australia and the U.K. Only Swedish gaming businesses detracted from the Fund’s overall positive performance.

 

Generic Drugs – Still a tough, but positive, environment

 

The Fund had a good six months, ending the period up 10.78%. Following steady gains through the fourth quarter 2017, generic drugs stocks (perhaps somewhat surprisingly) also faced a significant sell-off in early February 2018 from which they failed to recover fully by the end of the six-month reporting period. But they still remained up over the full period under review.

 

The biotechnology and pharmaceuticals sectors contributed the most to the Fund’s performance. The majority of negative performance was provided by the chemicals sector. In terms of individual companies, South Korean company Celltrion (8.0% of Fund net assets) was the single largest contributor to performance. U.S. company Albemarle (3.0% of Fund net assets) was the single largest detractor from performance.

 

Pharmaceutical – Not helped by State of the Union address

 

Pharmaceutical stocks had a lackluster six months. However, unlike biotech stocks, they ended the period down only 1.24%. Having hit a high for the period toward the end of January, pharma stocks plummeted in the selloff thereafter, hitting a low in early-February and slumping thereafter further, if fitfully, through to the end of March. Along with biotech stocks, they, too, were not helped by the mention of drugs prices in President Trump’s State of the Union address.

 

While Mylan and Zoetis (4.4% and 4.7% of Fund net assets, respectively) were the two largest positive contributors to performance, Mallinckrodt and Sanofi (0.7% and 5.1% of Fund net assets, respectively) were the Fund’s two largest detractors.

 

Retail – eCommerce remains solid

 

The Fund returned a very healthy 16.26% for the six-month period under review. Retail sales (excluding automobiles, gasoline stations, and restaurants) in the U.S. over the last three months of 2017 proved to be robust. Following retail sales up 4.3% in October,8 in November and December, sales increased 5.5% over 2016 to reach $691.9 billion.9 This included some $138.4 billion in online and other non-store sales, up 11.5% over 2016.10 These sales results beat the National Retail Federation forecast of approximately between $678 billion and $682 billion. The 5.5% was the largest increase since that of 5.2% seen in 2010.11 2018 started strongly with retail sales (excluding automobiles, gasoline stations, and restaurants) in January, up 5.4% on 2017.12 Although growth in February was a little slower, 4.4% year over year and 0.3% (seasonally adjusted) up in January,13 according to National Retail Federation Chief Economist Jack Kleinhenz: “With consumer confidence and employment growing, economic fundamentals are favorable for spending to expand in the coming months.”14

 

While stores involved in Internet and catalog retailing, in particular Amazon.com (19.3% of Fund net assets), contributed by far the most to the positive performance of the Fund, both specialty and multiline retailers also made useful contributions to performance. Health care providers and services companies detracted from performance.

4

 

 

Semiconductor – Industry sales continue to boom

 

The Fund returned 13.36% for the six-month period under review. Global sales for 2017 of $412.2 billion were 21.6% higher than those in 2016. In addition, sales for December 2017 ($38.0 billion) and the fourth quarter 2017 ($114.0 billion) were the highest monthly and quarterly sales respectively ever recorded.15 Thereafter semiconductor sales in the first two months of 2018 also remained strong. In January, sales were up 22.7% compared to January 2017 and the market grew year over year for the eighteenth consecutive month.16 While in February, sales growth was a little down from January, they were still up 21% compared to February 2017.17

 

Large-capitalization stocks continued to be key drivers of SMH’s returns. Intel, Taiwan Semiconductor Manufacturing, and NVIDIA (8.1%, 7.8% and 5.1% of Fund net assets, respectively) were the three best performing companies. Advanced Micro Devices, Cadence Design, and Broadcom (2.4%, 2.2%, and 5.0% of Fund net assets, respectively) detracted most from the Fund’s performance.

 

All Fund assets referenced are Total Net Assets as of March 31, 2018.
   
 
1 CNN Money: Trump wants to fix ‘injustice’ of high drug prices. But can he?, http://money.cnn.com/2018/01/31/investing/trump-state-of-the-union-drug-prices/index.html
   
2 U.S. News: Health Stocks Pressured Under JPM-AMZN-BRK Venture, https://money.usnews.com/investing/stock-market-news/articles/2018-01-31/health-care-stocks-jpm-amzn-brk
   
3 Gaming Inspection and Coordination Bureau, Macao SAR: Monthly Gross Revenue from Games of Fortune, http://www.dicj.gov.mo/web/en/information/DadosEstat_mensal/2017/index.html
   
4 Ibid.
   
5 Gaming Inspection and Coordination Bureau, Macao SAR: Monthly Gross Revenue from Games of Fortune, http://www.dicj.gov.mo/web/en/information/DadosEstat_mensal/2018/index.html
   
6 Nevada Gaming Control Board: Abbreviated Revenue Release, http://gaming.nv.gov/index.aspx?page=172
   
7 Ibid.
   
8 National Retail Federation: October Retail Sales Up 4.3 Percent Over Last Year, https://nrf.com/media/press-releases/october-retail-sales-43-percent-over-last-year
   
9 National Retail Federation: Holiday Retail Sales Increased 5.5 Percent in 2017, Exceeding NRF Forecasts and Showing Strongest Gain Since Great Recession, https://nrf.com/media/press-releases/holiday-retail-sales-increased-55-percent-2017-exceeding-nrf-forecast-and
   
10 Ibid.
   
11 Ibid.
   
12 National Retail Federation: January Retail Sales Continue Strong After Holidays, Up 5.4 Percent Over Last Year, https://nrf.com/media/press-releases/january-retail-sales-continue-strong-after-holidays-54-percent-over-last-year
   
13 National Retail Federation: February Retail Sales Increase 4.4 Percent Over Last Year, https://nrf.com/media/press-releases/february-retail-sales-increase-44-percent-over-last-year
   
14 Ibid.
   
15 Semiconductor Industry Association: Annual Semiconductor Sales Increase 21.6 Percent, Top $400 Billion for First Time, https://www.semiconductors.org/news/2018/02/05/global_sales_report_2017/annual_semiconductor_sales_increase_21.6_percent_top_40 0_billion_for_first_time/
   
16 Semiconductor Industry Association: January Semiconductor Sales Up 22.7 Percent Compared to Last Year, https://www.semiconductors.org/news/2018/03/05/global_sales_report_2017/january_semiconductor_sales_up_22.7_percent_compared_ to_last_year/
   
17 Semiconductor Industry Association: Global Semiconductor Sales Up 21 Percent Year-to-Year in February, https://www.semiconductors.org/news/2018/04/02/global_sales_report_2017/global_semiconductor_sales_up_21_percent_year_to_year_in _february/
5

VANECK VECTORS ETF TRUST

EXPLANATION OF EXPENSES

(unaudited)

 

Hypothetical $1,000 investment at beginning of period

As a shareholder of a Fund, you incur operating expenses, including management fees and other Fund expenses. This disclosure is intended to help you understand the ongoing costs (in dollars) of investing in your Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

 

The disclosure is based on an investment of $1,000 invested at the beginning of the period and held for the entire period, October 1, 2017 to March 31, 2018.

 

Actual Expenses

The first line in the table below provides information about account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period.”

 

Hypothetical Example for Comparison Purposes

The second line in the table below provides information about hypothetical account values and hypothetical expenses based on the Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

 

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

 

   Beginning
Account
Value
October 1, 2017
  Ending
Account
Value
March 31, 2018
  Annualized
Expense
Ratio
During Period
  Expenses Paid
During the Period*
October 1, 2017 -
March 31, 2018
Biotech ETF                    
Actual  $1,000.00   $901.40    0.35%   $1.66 
Hypothetical**  $1,000.00   $1,023.19    0.35%   $1.77 
Environmental Services ETF                    
Actual  $1,000.00   $995.50    0.56%   $2.79 
Hypothetical**  $1,000.00   $1,022.14    0.56%   $2.82 
Gaming ETF                    
Actual  $1,000.00   $1,108.90    0.65%   $3.42 
Hypothetical**  $1,000.00   $1,021.69    0.65%   $3.28 
Generic Drugs ETF                    
Actual  $1,000.00   $1,107.80    0.55%   $2.89 
Hypothetical**  $1,000.00   $1,022.19    0.55%   $2.77 
Pharmaceutical ETF                    
Actual  $1,000.00   $987.60    0.36%   $1.78 
Hypothetical**  $1,000.00   $1,023.14    0.36%   $1.82 
Retail ETF                    
Actual  $1,000.00   $1,162.60    0.35%   $1.89 
Hypothetical**  $1,000.00   $1,023.19    0.35%   $1.77 
Semiconductor ETF                    
Actual  $1,000.00   $1,133.60    0.35%   $1.86 
Hypothetical**  $1,000.00   $1,023.19    0.35%   $1.77 

 

* Expenses are equal to the Fund’s annualized expense ratio (for the six months ended March 31, 2018) multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year divided by the number of days in the fiscal year (to reflect the one-half year period).
   
** Assumes annual return of 5% before expenses
6

VANECK VECTORS BIOTECH ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value
     
COMMON STOCKS: 100.0%    
Ireland: 1.6%    
 118,991   Alkermes Plc (USD) *  $6,896,718 
Netherlands: 2.7%     
 371,336   QIAGEN NV (USD) *   11,997,866 
Spain: 2.4%     
 499,074   Grifols SA (ADR)   10,580,369 
United States: 93.3%     
 172,056   Alexion Pharmaceuticals, Inc. *   19,177,362 
 147,680   Allergan Plc   24,853,067 
 67,245   Alnylam Pharmaceuticals, Inc. *   8,008,880 
 282,165   Amgen, Inc.   48,103,489 
 85,121   Biogen Idec, Inc. *   23,307,832 
 237,412   BioMarin Pharmaceutical, Inc. *   19,246,991 
 31,444   Bluebird Bio, Inc. *   5,369,063 
 356,566   Celgene Corp. *   31,809,253 
 79,883   Charles River Laboratories International, Inc. *   8,526,711 
 613,274   Gilead Sciences, Inc.   46,234,727 
 84,393   Illumina, Inc. *   19,952,193 
 222,428   Incyte Corp. *   18,534,925 
 115,186   Ionis Pharmaceuticals, Inc. *   5,077,399 
 200,020   IQVIA Holdings, Inc. *   19,623,962 
 172,081   Nektar Therapeutics *   18,285,327 
 104,240   Neurocrine Biosciences, Inc. *   8,644,623 
 61,064   Regeneron Pharmaceuticals, Inc. *   21,027,999 
 135,181   Seattle Genetics, Inc. *   7,075,374 
 169,121   Shire Plc (ADR)   25,264,986 
 40,397   TESARO, Inc. * †   2,308,285 
 64,089   United Therapeutics Corp. *   7,201,040 
 132,931   Vertex Pharmaceuticals, Inc. *   21,665,094 
         409,298,582 
Total Common Stocks
(Cost: $509,101,124)
   438,773,535 
Number
of Shares
       Value
             
MONEY MARKET FUND: 0.1%
(Cost: $379,960)
     
  379,960    Dreyfus Government Cash Management Fund – Institutional Shares  $379,960 
Total Investments Before Collateral for Securities Loaned: 100.1%
(Cost: $509,481,084)
   439,153,495 
      
Principal
Amount
          
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 0.4%     
Repurchase Agreements: 0.4%     
$ 1,000,000    Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $1,000,201; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $1,020,000 including accrued interest)   1,000,000 
  542,625    Repurchase agreement dated 3/29/18 with Mizuho Securities USA, Inc., 1.80%, due 4/2/18, proceeds $542,734; (collateralized by various U.S. government and agency obligations, 2.84% to 5.00%, due 12/1/24 to 12/15/47, valued at $553,478 including accrued interest)   542,625 
Total Short-Term Investments Held as Collateral for Securities on Loan
(Cost: $1,542,625)
   1,542,625 
Total Investments: 100.5%
(Cost: $511,023,709)
   440,696,120 
Liabilities in excess of other assets: (0.5)%   (2,044,592)
NET ASSETS: 100.0%  $438,651,528 


 

 
Definitions:
ADR American Depositary Receipt
USD United States Dollar
Footnotes:
* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $1,465,812.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments    Value 
Biotechnology   61.5%  $270,280,804 
Health Care   29.2    128,015,961 
Life Sciences Tools & Services   9.2    40,476,770 
Money Market Fund        0.1           379,960 
    100.0%  $439,153,495 

 

See Notes to Financial Statements

7

VANECK VECTORS BIOTECH ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
  Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $438,773,535   $       $     $438,773,535 
Money Market Fund   379,960              379,960 
Repurchase Agreements       1,542,625          1,542,625 
Total  $439,153,495   $1,542,625     $   $440,696,120 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

8

VANECK VECTORS ENVIRONMENTAL SERVICES ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value
           
COMMON STOCKS: 100.0%     
United Kingdom: 10.2%     
 23,150   Steris Plc (USD)  $2,161,284 
United States: 89.8%     
 24,439   ABM Industries, Inc.   818,218 
 37,258   Advanced Disposal Services, Inc. *   830,108 
 7,383   Cantel Medical Corp.   822,540 
 33,913   Casella Waste Systems, Inc. *   792,886 
 90,495   Ceco Environmental Corp.   402,703 
 16,516   Clean Harbors, Inc. *   806,146 
 55,012   Covanta Holding Corp. †   797,674 
 47,298   Darling International, Inc. *   818,255 
 18,566   Donaldson Company, Inc.   836,398 
 18,860   Heritage-Crystal Clean, Inc. *   444,153 
 27,659   Layne Christensen Co. * †   412,672 
 49,852   Newpark Resources, Inc. *   403,801 
 31,999   Republic Services, Inc.   2,119,294 
 12,610   Schnitzer Steel Industries, Inc.   407,934 
 13,797   Stericycle, Inc. * †   807,538 
 12,188   Tennant Co. †   825,128 
 15,224   Tenneco, Inc.   835,341 
 16,493   Tetra Tech, Inc.   807,332 
 15,393   US Ecology, Inc.   820,447 
 29,534   Waste Connections, Inc.   2,118,769 
 25,299   Waste Management, Inc.   2,128,152 
         19,055,489 
Total Common Stocks
(Cost: $19,471,613)
   21,216,773 
MONEY MARKET FUND: 0.3%
(Cost: $52,946)
     
 52,946   Dreyfus Government Cash Management Fund – Institutional Shares   52,946 
Total Investments Before Collateral for Securities Loaned: 100.3%
(Cost: $19,524,559)
   21,269,719 
Principal
Amount
       Value
             
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 8.0%     
Repurchase Agreements: 8.0%     
$1,000,000     Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $1,000,201; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $1,020,000 including accrued interest)  $1,000,000 
 704,843     Repurchase agreement dated 3/29/18 with HSBC Securities USA, Inc., 1.79%, due 4/2/18, proceeds $704,983; (collateralized by various U.S. government and agency obligations, 2.50% to 8.00%, due 4/1/22 to 3/1/48, valued at $719,851 including accrued interest)   704,843 
Total Short-Term Investments Held as Collateral for Securities on Loan
(Cost: $1,704,843)
   1,704,843 
Total Investments: 108.3%
(Cost: $21,229,402)
   22,974,562 
Liabilities in excess of other assets: (8.3)%   (1,757,273)
NET ASSETS: 100.0%  $21,217,289 


 

 
Definitions:
USD United States Dollar
Footnotes:
* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $1,680,079.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments    Value 
Consumer Discretionary   3.9%  $835,341 
Consumer Staples   3.9    818,255 
Energy   1.9    403,801 
Health Care   14.0    2,983,824 
Industrials   74.2    15,767,618 
Materials   1.9    407,934 
Money Market Fund         0.2            52,946 
    100.0%  $21,269,719 

 

See Notes to Financial Statements

9

VANECK VECTORS ENVIRONMENTAL SERVICES ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $21,216,773   $       $     $21,216,773 
Money Market Fund   52,946              52,946 
Repurchase Agreements       1,704,843          1,704,843 
Total  $21,269,719   $1,704,843     $   $22,974,562 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

10

VANECK VECTORS GAMING ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number      
of Shares     Value
 
COMMON STOCKS: 97.3%   
Australia: 12.5%     
 170,561   Aristocrat Leisure Ltd. #  $3,180,319 
 97,286   Crown Ltd. #   954,208 
 185,971   Star Entertainment Group Ltd. #   760,302 
 506,146   TABCORP Holdings Ltd. #   1,714,159 
         6,608,988 
Cambodia: 1.0%     
 522,000   Nagacorp Ltd. #   543,372 
Canada: 1.3%    
 25,891   Stars Group, Inc. (USD) *   713,297 
China / Hong Kong: 26.6%     
 510,240   Galaxy Entertainment Group Ltd. #   4,683,244 
 22,620,000   Landing International Development Ltd. * #   635,520 
 74,013   Melco Crown Entertainment Ltd. (ADR)   2,144,897 
 194,000   Melco International Development Ltd. #   569,340 
 256,900   MGM China Holdings Ltd. † #   668,155 
 644,000   Sands China Ltd. #   3,499,644 
 663,000   SJM Holdings Ltd. #   580,839 
 366,800   Wynn Macau Ltd. #   1,344,382 
         14,126,021 
Greece: 1.4%    
 65,620   OPAP SA #   751,729 
Ireland: 3.6%     
 18,534   Paddy Power Betfair Plc   1,902,163 
Japan: 3.4%    
 17,500   Heiwa Corp. #   345,228 
 14,879   Sankyo Co. Ltd. #   520,773 
 56,400   Sega Sammy Holdings, Inc. #   914,284 
         1,780,285 
Malaysia: 2.1%    
 886,098   Genting Malaysia Bhd #   1,113,626 
Malta: 1.2%    
 45,218   Kindred Group Plc (LDR) #   618,520 
New Zealand: 0.7%     
 136,644   Sky City Entertainment Group Ltd. #   385,658 
Singapore: 2.7%     
 1,738,100   Genting Singapore Plc #   1,441,457 
South Africa: 0.7%     
 183,225   Tsogo Sun Holdings Ltd. #   359,713 
South Korea: 2.0%     
 30,215   Kangwon Land, Inc. #   774,589 
 15,636   Paradise Co. Ltd. #   301,975 
         1,076,564 
Sweden: 0.9%    
 31,504   Betsson AB #   237,890 
 50,713   NetEnt AB #   255,236 
         493,126 
United Kingdom: 5.7%     
 111,850   GVC Holdings Plc † #   1,445,064 
 59,433   Playtech Ltd. #   611,173 
 206,701   William Hill Plc #   958,249 
         3,014,486 
Number      
of Shares     Value
 
United States: 31.5%      
 17,962   Boyd Gaming Corp.  $572,269 
 186,986   Caesars Entertainment Corp. *   2,103,592 
 2,530   Churchill Downs, Inc.   617,446 
 15,889   Eldorado Resorts, Inc. * †   524,337 
 30,455   International Game Technology Plc   814,062 
 59,180   Las Vegas Sands Corp.   4,255,042 
 108,496   MGM Resorts International   3,799,530 
 15,199   Penn National Gaming, Inc. *   399,126 
 10,496   Scientific Games Corp. * †   436,634 
 17,646   Wynn Resorts Ltd.   3,217,925 
         16,739,963 
Total Common Stocks
(Cost: $50,518,588)
   51,668,968 
REAL ESTATE INVESTMENT TRUSTS: 2.8%
(Cost: $1,586,127)
      
United States: 2.8%      
 43,206   Gaming and Leisure Properties, Inc.   1,446,105 
Total Investments Before Collateral for Securities Loaned: 100.1%
(Cost: $52,104,715)
   53,115,073 
           
Principal         
Amount         
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 4.2%
Repurchase Agreements: 4.2%     
$239,962   Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.80%, due 4/2/18, proceeds $240,010; (collateralized by various U.S. government and agency obligations, 0.00% to 4.75%, due 4/12/18 to 9/9/49, valued at $244,761 including accrued interest)   239,962 
 1,000,000   Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $1,000,201; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $1,020,000 including accrued interest)   1,000,000 
 1,000,000   Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $1,000,202; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $1,020,000 including accrued interest)   1,000,000 
Total Short-Term Investments Held as Collateral for Securities on Loan
(Cost: $2,239,962)
   2,239,962 
Total Investments: 104.3%
(Cost: $54,344,677)
   55,355,035 
Liabilities in excess of other assets: (4.3)%   (2,264,512)
NET ASSETS: 100.0%  $53,090,523 


 

See Notes to Financial Statements

11

VANECK VECTORS GAMING ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

Definitions:

ADR American Depositary Receipt
LDR Local Depositary Receipt
USD United States Dollar

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $2,144,566.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $30,168,648 which represents 56.8% of net assets.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments     Value 
Consumer Discretionary   95.6%  $50,778,212 
Information Technology   1.7    890,756 
Real Estate           2.7           1,446,105 
    100.0%  $53,115,073 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

       Level 2   Level 3    
   Level 1   Significant   Significant    
   Quoted   Observable   Unobservable    
   Prices   Inputs   Inputs  Value 
Common Stocks                      
Australia  $   $6,608,988       $     $6,608,988 
Cambodia       543,372          543,372 
Canada   713,297              713,297 
China / Hong Kong   2,144,897    11,981,124          14,126,021 
Greece       751,729          751,729 
Ireland   1,902,163              1,902,163 
Japan       1,780,285          1,780,285 
Malaysia       1,113,626          1,113,626 
Malta       618,520          618,520 
New Zealand       385,658          385,658 
Singapore       1,441,457          1,441,457 
South Africa       359,713          359,713 
South Korea       1,076,564          1,076,564 
Sweden       493,126          493,126 
United Kingdom       3,014,486          3,014,486 
United States   16,739,963              16,739,963 
Real Estate Investment Trusts*   1,446,105              1,446,105 
Repurchase Agreements       2,239,962          2,239,962 
Total  $22,946,425   $32,408,610     $   $55,355,035 

 

* See Schedule of Investments for geographic sector breakouts.

 

During the period ended March 31, 2018, transfers of securities from Level 1 to Level 2 were $4,313,953. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements

See Notes to Financial Statements

12

VANECK VECTORS GENERIC DRUGS ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number        
of Shares      Value
  
COMMON STOCKS: 100.1%     
Belgium: 4.6%    
 2,057   UCB SA #  $167,437 
China / Hong Kong: 13.1%    
 66,000   CSPC Pharmaceutical Group Ltd. #   177,901 
 1,600   Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. #   4,963 
 5,000   Shanghai Fosun Pharmaceutical Group Co. Ltd. #   30,975 
 9,700   Shanghai Pharmaceuticals Holding Co. Ltd. #   26,110 
 89,000   Sino Biopharmaceutical Ltd. #   176,875 
 12,800   Sinopharm Group Co. Ltd.   64,095 
         480,919 
Finland: 0.9%    
 1,102   Orion OYJ #   33,719 
Germany: 1.8%    
 659   Stada Arzneimittel AG   67,788 
Hungary: 1.1%    
 1,971   Richter Gedeon Nyrt #   41,191 
India: 16.0%    
 6,197   Aurobindo Pharma Ltd. #   53,392 
 6,346   Biocon Ltd. #   58,160 
 10,829   Cadila Healthcare Ltd. #   63,239 
 8,516   Cipla Ltd. #   71,390 
 1,754   Dr Reddy’s Laboratories Ltd. (ADR)   57,338 
 4,782   Lupin Ltd. #   54,228 
 25,378   Sun Pharmaceuticals Industries Ltd. #   193,978 
 1,790   Torrent Pharmaceuticals Ltd. #   34,489 
         586,214 
Indonesia: 1.5%     
 495,800   Kalbe Farma Tbk PT #   54,188 
Ireland: 7.8%    
 1,652   Alkermes Plc (USD) *   95,750 
 572   ICON Plc (USD) *   67,576 
 1,490   Perrigo Co. Plc (USD)   124,177 
         287,503 
Israel: 6.2%    
 424   Taro Pharmaceutical Industries Ltd. (USD) *   41,866 
 10,756   Teva Pharmaceutical Industries Ltd. (ADR)   183,820 
         225,686 
Japan: 8.4%    
 1,000   Hisamitsu Pharmaceutical Co., Inc. #   77,343 
 6,100   Kyowa Hakko Kirin Co. Ltd. #   132,546 
 1,000   Taisho Pharmaceutical Holdings Co. Ltd. #   98,918 
         308,807 
Jordan: 1.2%    
 2,546   Hikma Pharmaceuticals Plc (GBP) † #   43,293 
South Africa: 2.9%    
 4,828   Aspen Pharmacare Holdings Ltd. #   105,845 
Number        
of Shares      Value
           
South Korea: 9.6%     
 981   Celltrion, Inc. * #  $293,463 
 672   Hanmi Science Co. Ltd. #   60,067 
         353,530 
Switzerland: 5.1%     
 788   Lonza Group AG #   185,531 
United States: 19.9%     
 1,170   Albemarle Corp. †   108,506 
 502   Charles River Laboratories International, Inc. *   53,584 
 2,203   IQVIA Holdings, Inc. *   216,136 
 913   Mallinckrodt Plc * †   13,220 
 5,445   Mylan NV *   224,171 
 5,918   Opko Health, Inc. * †   18,760 
 675   PRA Health Sciences, Inc. *   55,998 
 1,104   Syneos Health, Inc. *   39,192 
         729,567 
Total Common Stocks
(Cost: $3,518,125)
   3,671,218 
MONEY MARKET FUND: 1.2%
(Cost: $44,394)
     
 44,394   Dreyfus Government Cash Management Fund – Institutional Shares   44,394 
Total Investments Before Collateral for Securities Loaned: 101.3%
(Cost: $3,562,519)
   3,715,612 
           
Principal
Amount
         
SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES ON LOAN: 4.7%
(Cost: $170,345)
Repurchase Agreement: 4.7%     
$170,345   Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.80%, due 4/2/18, proceeds $170,379; (collateralized by various U.S. government and agency obligations, 0.00% to 4.75%, due 4/12/18 to 9/9/49, valued at $173,752 including accrued interest)   170,345 
Total Investments: 106.0%
(Cost: $3,732,864)
   3,885,957 
Liabilities in excess of other assets: (6.0)%   (218,669)
NET ASSETS: 100.0%  $3,667,288 


 

See Notes to Financial Statements

13

VANECK VECTORS GENERIC DRUGS ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

Definitions:

ADR American Depositary Receipt
GBP British Pound
USD United States Dollar

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $170,906.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $2,239,241 which represents 61.1% of net assets.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments     Value 
Biotechnology   12.6%  $466,133 
Health Care Distributors   2.4    90,205 
Life Sciences Tools & Services   16.6    618,017 
Pharmaceuticals   64.3    2,388,357 
Specialty Chemicals   2.9    108,506 
Money Market Fund           1.2            44,394 
    100.0%  $3,715,612 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks                      
Belgium  $   $167,437       $     $167,437 
China / Hong Kong   64,095    416,824          480,919 
Finland       33,719          33,719 
Germany   67,788              67,788 
Hungary       41,191          41,191 
India   57,338    528,876          586,214 
Indonesia       54,188          54,188 
Ireland   287,503              287,503 
Israel   225,686              225,686 
Japan       308,807          308,807 
Jordan       43,293          43,293 
South Africa       105,845          105,845 
South Korea       353,530          353,530 
Switzerland       185,531          185,531 
United States   729,567              729,567 
Money Market Fund   44,394              44,394 
Repurchase Agreement       170,345          170,345 
Total  $1,476,371   $2,409,586     $   $3,885,957 

 

During the period ended March 31, 2018, transfers of securities from Level 1 to Level 2 were $154,390, and transfers of securities from Level 2 to Level 1 were $53,386. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.

 

See Notes to Financial Statements 

14

VANECK VECTORS PHARMACEUTICAL ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value
 
COMMON STOCKS: 99.6%      
Denmark: 5.0%     
 247,277   Novo-Nordisk AS (ADR)  $12,178,392 
France: 5.1%     
 313,775   Sanofi SA (ADR)   12,576,102 
Ireland: 10.2%     
 343,897   Endo International Plc (USD) *   2,042,748 
 77,553   Jazz Pharmaceuticals Plc (USD) *   11,709,727 
 135,984   Perrigo Co. Plc (USD)   11,332,907 
         25,085,382 
Israel: 4.1%     
 590,857   Teva Pharmaceutical Industries Ltd. (ADR) †   10,097,746 
Switzerland: 5.0%      
 152,995   Novartis AG (ADR)   12,369,646 
United Kingdom: 12.6%      
 371,391   AstraZeneca Plc (ADR)   12,987,543 
 336,007   GlaxoSmithKline Plc (ADR) †   13,127,794 
 42,052   GW Pharmaceuticals Plc (ADR) *   4,737,999 
         30,853,336 
United States: 57.6%      
 109,132   AbbVie, Inc.   10,329,344 
 160,727   Akorn, Inc. *   3,007,202 
 117,862   AmerisourceBergen Corp.   10,160,883 
 189,405   Bristol-Myers Squibb Co.   11,979,866 
 208,394   Catalent, Inc. *   8,556,658 
 145,502   Eli Lilly & Co.   11,257,490 
 97,022   Johnson & Johnson   12,433,369 
 124,904   Mallinckrodt Plc * †   1,808,610 
 74,251   McKesson Corp.   10,459,738 
 229,844   Merck and Co., Inc.   12,519,603 
 265,183   Mylan NV *   10,917,584 
 123,638   Patterson Companies, Inc. †   2,748,473 
 348,445   Pfizer, Inc.   12,366,313 
 723,123   Valeant Pharmaceuticals International, Inc. * †   11,512,118 
 137,814   Zoetis, Inc.   11,508,847 
         141,566,098 
Total Common Stocks
(Cost: $325,158,768)
   244,726,702  
MONEY MARKET FUND: 0.1%
(Cost: $253,687)
     
 253,687   Dreyfus Government Cash Management Fund – Institutional Shares   253,687 
Total Investments Before Collateral for Securities Loaned: 99.7%
(Cost: $325,412,455)
   244,980,389  
Principal
Amount
       
Value
 
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 11.7%  
Repurchase Agreements: 11.7%      
$6,846,752   Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $6,848,137; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $6,983,687 including accrued interest)  $6,846,752 
 1,440,198   Repurchase agreement dated 3/29/18 with Credit Agricole CIB, 1.75%, due 4/2/18, proceeds $1,440,478; (collateralized by various U.S. government and agency obligations, 1.50% to 1.63%, due 12/31/18 to 10/15/20, valued at $1,469,002 including accrued interest)   1,440,198 
 6,846,752   Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $6,848,129; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $6,983,687 including accrued interest)   6,846,752 
 6,846,752   Repurchase agreement dated 3/29/18 with HSBC Securities USA, Inc., 1.78%, due 4/2/18, proceeds $6,848,106; (collateralized by various U.S. government and agency obligations, 0.00% to 7.25%, due 5/15/18 to 1/15/37, valued at $7,008,651 including accrued interest)   6,846,752 
 6,846,752   Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $6,848,137; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $6,983,687 including accrued interest)   6,846,752 
Total Short-Term Investments Held as Collateral for Securities on Loan
(Cost: $28,827,206)
   28,827,206  
Total Investments: 111.4%
(Cost: $354,239,661)
   273,807,595  
Liabilities in excess of other assets: (11.4)%   (27,921,736 )
NET ASSETS: 100.0% $ 245,885,859  


 

See Notes to Financial Statements

15

VANECK VECTORS PHARMACEUTICAL ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

Definitions:

ADR American Depositary Receipt
USD United States Dollar

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $28,238,597.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments  Value 
Health Care   24.9%  $61,099,672 
Pharmaceuticals   75.0    183,627,030 
Money Market Fund   0.1    253,687 
              100.0%  $244,980,389 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $244,726,702   $       $     $244,726,702 
Money Market Fund   253,687              253,687 
Repurchase Agreements       28,827,206          28,827,206 
Total  $244,980,389   $28,827,206     $   $273,807,595 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

16

VANECK VECTORS RETAIL ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value
 
COMMON STOCKS: 100.1%      
China / Hong Kong: 2.9%      
 47,792   JD.com, Inc. (ADR) *  $1,935,098 
United States: 97.2%      
 8,967   Amazon.com, Inc. *   12,978,298 
 12,779   AmerisourceBergen Corp.   1,101,678 
 1,591   AutoZone, Inc. *   1,032,066 
 17,006   Best Buy Co., Inc.   1,190,250 
 18,308   Cardinal Health, Inc.   1,147,545 
 18,486   Costco Wholesale Corp.   3,483,317 
 46,174   CVS Caremark Corp.   2,872,484 
 16,057   Dollar General Corp.   1,502,132 
 17,411   Dollar Tree, Inc. *   1,652,304 
 42,617   Home Depot, Inc.   7,596,054 
 10,735   Kohl’s Corp.   703,250 
 66,403   Kroger Co.   1,589,688 
 13,729   L Brands, Inc.   524,585 
 40,223   Lowe’s Cos, Inc.   3,529,568 
 23,545   MACY’S, Inc.   700,228 
 14,562   McKesson Corp.   2,051,349 
 6,144   O’Reilly Automotive, Inc. *   1,519,903 
 28,062   Ross Stores, Inc.   2,188,275 
 36,335   Sysco Corp.   2,178,647 
 38,744   Target Corp.   2,689,996 
 25,588   The Gap, Inc.   798,346 
 37,725   TJX Cos., Inc.   3,076,851 
 44,852   Walgreens Boots Alliance, Inc.   2,936,460 
 71,162   Wal-Mart Stores, Inc.   6,331,283 
         65,374,557 
Total Common Stocks
(Cost: $72,260,522)
   67,309,655  
Number
of Shares
      Value
 
MONEY MARKET FUND: 0.0%      
(Cost: $7,123)      
 7,123   Dreyfus Government Cash Management Fund – Institutional Shares  $7,123 
Total Investments: 100.1%
(Cost: $72,267,645)
   67,316,778  
Liabilities in excess of other assets: (0.1)%   (72,295 )
NET ASSETS: 100.0% $ 67,244,483  


 

 

Definitions:

ADR American Depositary Receipt
Footnotes:
* Non-income producing

 

Summary of Investments by Sector  % of Investments  Value 
Consumer Discretionary   64.8%  $43,617,204 
Consumer Staples   28.8    19,391,879 
Health Care   6.4    4,300,572 
Money Market Fund   0.0    7,123 
              100.0%  $67,316,778 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
  Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $67,309,655       $         $     $67,309,655 
Money Market Fund   7,123                7,123 
Total  $67,316,778     $     $   $67,316,778 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

17

VANECK VECTORS SEMICONDUCTOR ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value
     
COMMON STOCKS: 99.9%    
Bermuda: 2.2%    
 1,110,912   Marvell Technology Group Ltd. (USD)  $23,329,152 
Netherlands: 9.6%     
 274,091   ASML Holding NV (USD)   54,423,509 
 409,721   NXP Semiconductors NV (USD) *   47,937,357 
         102,360,866 
Taiwan: 7.8%     
 1,919,727   Taiwan Semiconductor Manufacturing Co. Ltd. (ADR)   84,007,254 
United States: 80.3%     
 2,529,691   Advanced Micro Devices, Inc. * †   25,423,395 
 546,899   Analog Devices, Inc.   49,838,906 
 949,700   Applied Materials, Inc.   52,812,817 
 227,502   Broadcom Ltd.   53,610,846 
 643,229   Cadence Design Systems, Inc. *   23,651,530 
 163,738   Cavium, Inc. *   12,997,522 
 1,665,398   Intel Corp.   86,733,928 
 387,959   KLA-Tencor Corp.   42,291,411 
 239,817   Lam Research Corp.   48,721,222 
 687,016   Maxim Integrated Products, Inc.   41,372,104 
 530,895   Microchip Technology, Inc. †   48,502,567 
 1,045,671   Micron Technology, Inc. *   54,521,286 
 267,700   Microsemi Corp. *   17,325,544 
 234,138   NVIDIA Corp.   54,224,019 
 966,701   ON Semiconductor Corp. *   23,645,506 
 212,122   Qorvo, Inc. * †   14,943,995 
 899,908   Qualcomm, Inc.   49,863,902 
 433,737   Skyworks Solutions, Inc.   43,486,472 
 529,237   Teradyne, Inc.   24,191,423 
 519,401   Texas Instruments, Inc.   53,960,570 
 537,532   Xilinx, Inc.   38,831,312 
         860,950,277 
Total Common Stocks
(Cost: $1,160,384,582)
   1,070,647,549 
MONEY MARKET FUND: 0.1%
(Cost: $1,253,516)
     
 1,253,516   Dreyfus Government Cash Management Fund – Institutional Shares   1,253,516 
Total Investments Before Collateral for Securities Loaned: 100.0%
(Cost: $1,161,638,098)
   1,071,901,065 
Principal
Amount
        Value
        
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 2.7%  
Repurchase Agreements: 2.7%       
$ 6,909,356   Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $6,910,753; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $7,047,543 including accrued interest)  $ 6,909,356  
  1,452,971   Repurchase agreement dated 3/29/18 with Credit Agricole CIB, 1.75%, due 4/2/18, proceeds $1,453,254; (collateralized by various U.S. government and agency obligations, 1.50% to 1.63%, due 12/31/18 to 10/15/20, valued at $1,482,031 including accrued interest)    1,452,971  
  6,909,356   Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $6,910,746; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $7,047,543 including accrued interest)    6,909,356  
  6,909,356   Repurchase agreement dated 3/29/18 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.81%, due 4/2/18, proceeds $6,910,746; (collateralized by various U.S. government and agency obligations, 0.00% to 4.50%, due 12/1/26 to 4/1/48, valued at $7,047,543 including accrued interest)    6,909,356  
  6,909,356   Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $6,910,753; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $7,047,543 including accrued interest)    6,909,356  
Total Short-Term Investments Held as Collateral for Securities on Loan
(Cost: $29,090,395)
    29,090,395  
Total Investments: 102.7%
(Cost: $1,190,728,493)
    1,100,991,460  
Liabilities in excess of other assets: (2.7)%    (29,287,783 )
NET ASSETS: 100.0%  $ 1,071,703,677  


 

See Notes to Financial Statements

18

 

 

Definitions:
ADR American Depositary Receipt
USD United States Dollar
Footnotes:
* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $28,540,980.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments  Value 
Information Technology   16.1%  $172,393,339 
Semiconductor Equipment   20.8    222,440,382 
Semiconductors   63.0    675,813,828 
Money Market Fund   0.1    1,253,516 
              100.0%  $1,071,901,065 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $1,070,647,549   $       $     $1,070,647,549 
Money Market Fund   1,253,516              1,253,516 
Repurchase Agreements       29,090,395          29,090,395 
Total  $1,071,901,065   $29,090,395     $   $1,100,991,460 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

19

VANECK VECTORS ETF TRUST

STATEMENTS OF ASSETS AND LIABILITIES

March 31, 2018 (unaudited)

 

   Biotech
ETF
   Environmental
Services
ETF
   Gaming
ETF
   Generic
Drugs
ETF
 
Assets:                    
Investments, at value                    
Unaffiliated issuers (1) (2)  $439,153,495   $21,269,719   $53,115,073   $3,715,612 
Short-term investments held as collateral for securities loaned (3)   1,542,625    1,704,843    2,239,962    170,345 
Cash                
Cash denominated in foreign currency, at value (4)               2,458 
Receivables:                    
Investment securities sold       790,975    812,481    1,381 
Shares sold                
Due from Adviser               5,667 
Dividends   180,021    24,454    205,382    3,106 
Prepaid expenses   8,510    178    259    36 
Total assets   440,884,651    23,790,169    56,373,157    3,898,605 
                     
Liabilities:                    
Payables:                    
Investment securities purchased       807,462    812,843    1,376 
Collateral for securities loaned   1,542,625    1,704,843    2,239,962    170,345 
Line of credit   455,842        146,004     
Shares redeemed                
Due to Adviser   123,833    2,855    20,326     
Due to custodian           2,868     
Deferred Trustee fees   37,605    2,503    6,381    14 
Accrued expenses   73,218    55,217    54,250    59,582 
Total liabilities   2,233,123    2,572,880    3,282,634    231,317 
NET ASSETS  $438,651,528   $21,217,289   $53,090,523   $3,667,288 
Shares outstanding   3,646,503    250,000    1,150,000    150,000 
Net asset value, redemption and offering price per share  $120.29   $84.87   $46.17   $24.45 
                     
Net assets consist of:                    
Aggregate paid in capital  $507,455,197   $26,135,441   $57,948,668   $3,727,174 
Net unrealized appreciation (depreciation)   (70,327,589)   1,745,160    1,011,830    153,287 
Undistributed (accumulated) net investment income (loss)   557,375    36,954    345,277    (36,778)
Accumulated net realized gain (loss)   966,545    (6,700,266)   (6,215,252)   (176,395)
   $438,651,528   $21,217,289   $53,090,523   $3,667,288 
(1) Value of securities on loan  $1,465,812   $1,680,079   $2,144,566   $170,906 
(2) Cost of investments  $509,481,084   $19,524,559   $52,104,715   $3,562,519 
(3) Cost of short-term investments held as collateral for securities loaned  $1,542,625   $1,704,843   $2,239,962   $170,345 
(4) Cost of cash denominated in foreign currency  $   $   $   $2,413 

 

See Notes to Financial Statements

20

VANECK VECTORS ETF TRUST

STATEMENTS OF ASSETS AND LIABILITIES

March 31, 2018 (unaudited)

 

   Pharmaceutical
ETF
   Retail
ETF
   Semiconductor
ETF
         
Assets:                       
Investments, at value                       
Unaffiliated issuers (1) (2)  $244,980,389   $67,316,778   $1,071,901,065         
Short-term investments held as collateral for securities loaned (3)   28,827,206        29,090,395         
Cash   73,719        132,728         
Receivables:                       
Shares sold           3,445         
Dividends   952,272    68,702    83,550         
Prepaid expenses   5,281    753    8,110         
Total assets   274,838,867    67,386,233    1,101,219,293         
                        
Liabilities:                       
Payables:                       
Collateral for securities loaned   28,827,206        29,090,395         
Line of credit       72,801             
Shares redeemed   244                 
Due to Adviser   60,527    11,095    369,674         
Deferred Trustee fees   22,667    5,143    26,928         
Accrued expenses   42,364    52,711    28,619         
Total liabilities   28,953,008    141,750    29,515,616         
NET ASSETS  $245,885,859   $67,244,483   $1,071,703,677         
Shares outstanding   4,338,138    721,531    10,270,937         
Net asset value, redemption and offering price per share  $56.68   $93.20   $104.34         
                        
Net assets consist of:                       
Aggregate paid in capital  $316,966,079   $69,947,091   $960,976,912         
Net unrealized depreciation   (80,432,066)   (4,950,867)   (89,737,033)        
Undistributed net investment income   1,681,200    196,912    903,403         
Accumulated net realized gain   7,670,646    2,051,347    199,560,395         
   $245,885,859   $67,244,483   $1,071,703,677         
(1) Value of securities on loan  $28,238,597   $   $28,540,980         
(2) Cost of investments  $325,412,455   $72,267,645   $1,161,638,098         
(3) Cost of short-term investments held as collateral for securities loaned  $28,827,206   $   $29,090,395         
(4) Cost of cash denominated in foreign currency  $   $   $         

 

See Notes to Financial Statements

21

VANECK VECTORS ETF TRUST

STATEMENTS OF OPERATIONS

For the Six Months Ended March 31, 2018 (unaudited)

 

   Biotech
ETF
   Environmental
Services
ETF
   Gaming
ETF
   Generic
Drugs
ETF
 
Income:                    
Dividends  $2,390,386   $119,874   $595,187   $7,921 
Securities lending income   19,242    1,756    3,441    681 
Foreign taxes withheld   (39,167)   (1,136)   (16,786)   (814)
Total income   2,370,461    120,494    581,842    7,788 
                     
Expenses:                    
Management fees   1,063,068    45,456    107,812    9,053 
Professional fees   43,337    30,709    30,689    30,428 
Insurance   3,345    100    186    18 
Trustees’ fees and expenses   7,234    180    372    7 
Reports to shareholders   25,027    6,239    7,658    6,603 
Indicative optimized portfolio value fee   2,519        3,388    2,528 
Custodian fees   9,423    1,266    6,439    7,436 
Registration fees   2,922    2,967    3,202    2,178 
Transfer agent fees   1,212    1,212    1,211    1,212 
Fund accounting fees   20,432    529    1,911    1,135 
Interest   3,847    672    1,269    70 
Other   9,822    2,742    3,343    3,129 
Total expenses   1,192,188    92,072    167,480    63,797 
Waiver of management fees   (125,271)   (41,398)   (26,055)   (9,053)
Expenses assumed by the Adviser               (44,715)
Net expenses   1,066,917    50,674    141,425    10,029 
Net investment income (loss)   1,303,544    69,820    440,417    (2,241)
                     
Net realized gain (loss) on:                    
Investments   (779,558)   92,746    (511,867)   53,543 
In-kind redemptions   14,205,610        1,013,278     
Foreign currency transactions and foreign denominated assets and liabilities           (2,682)   (383)
Net realized gain   13,426,052    92,746    498,729    53,160 
                     
Net change in unrealized appreciation (depreciation) on:                    
Investments   (74,582,338)   (283,680)   1,989,230    310,438 
Foreign currency transactions and foreign denominated assets and liabilities           1,396    122 
Net change in unrealized appreciation (depreciation)   (74,582,338)   (283,680)   1,990,626    310,560 
Net Increase (Decrease) in Net Assets Resulting from Operations  $(59,852,742)  $(121,114)  $2,929,772   $361,479 

 

See Notes to Financial Statements

22

VANECK VECTORS ETF TRUST

STATEMENTS OF OPERATIONS

For the Six Months Ended March 31, 2018 (unaudited)

 

   Pharmaceutical
ETF
   Retail
ETF
   Semiconductor
ETF
     
Income:                    
Dividends  $3,007,526   $486,490   $5,941,137      
Securities lending income   18,592    646    57,229      
Foreign taxes withheld   (105,770)             
Total income   2,920,348    487,136    5,998,366      
                     
Expenses:                    
Management fees   474,839    110,625    2,070,564      
Professional fees   35,981    34,996    44,674      
Insurance   1,374    269    2,464      
Trustees’ fees and expenses   3,033    528    5,561      
Reports to shareholders   13,443    13,781    17,512      
Indicative optimized portfolio value fee   2,531    2,519    2,531      
Custodian fees   4,546    3,094    11,983      
Registration fees   3,044    2,543    2,552      
Transfer agent fees   1,211    1,186    1,211      
Fund accounting fees   8,707    1,834    23,462      
Interest   6,860    513    25,658      
Other   3,259    2,618    8,219      
Total expenses   558,828    174,506    2,216,391      
Waiver of management fees   (77,130)   (63,367)   (120,170)     
Net expenses   481,698    111,139    2,096,221      
Net investment income (loss)   2,438,650    375,997    3,902,145      
                     
Net realized gain (loss) on:                    
Investments   491,573    (496,834)   (287,984)     
In-kind redemptions   19,260,534    5,336,571    201,922,502      
Net realized gain   19,752,107    4,839,737    201,634,518      
                     
Net change in unrealized appreciation (depreciation) on:                    
Investments   (20,076,520)   3,136,221    (85,649,002)     
Net change in unrealized appreciation (depreciation)   (20,076,520)   3,136,221    (85,649,002)     
Net Increase (Decrease) in Net Assets Resulting from Operations  $2,114,237   $8,351,955   $119,887,661      

 

See Notes to Financial Statements

23

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   Biotech ETF   Environmental Services ETF 
   For the Period   For the Year   For the Period   For the Year 
   Ended   Ended   Ended   Ended 
   March 31,   September 30,   March 31,   September 30, 
   2018   2017   2018   2017 
   (unaudited)       (unaudited)     
                 
Operations:                    
Net investment income  $1,303,544   $3,140,614   $69,820   $159,868 
Net realized gain   13,426,052    14,003,280    92,746    3,729,077 
Net change in unrealized appreciation (depreciation)   (74,582,338)   84,996,662    (283,680)   178,828 
Net increase (decrease) in net assets resulting from operations   (59,852,742)   102,140,556    (121,114)   4,067,773 
                     
Dividends to shareholders:                    
Dividends from net investment income   (3,276,012)   (1,715,606)   (155,000)   (132,750)
                     
Share transactions:**                    
Proceeds from sale of shares   32,367,461    188,497,661    4,289,191    12,005,278 
Cost of shares redeemed   (247,917,612)   (170,506,515)       (16,156,568)
Increase (Decrease) in net assets resulting from share transactions   (215,550,151)   17,991,146    4,289,191    (4,151,290)
Total increase (decrease) in net assets   (278,678,905)   118,416,096    4,013,077    (216,267)
Net Assets, beginning of period   717,330,433    598,914,337    17,204,212    17,420,479 
Net Assets, end of period†  $438,651,528   $717,330,433   $21,217,289   $17,204,212 
† Including undistributed net investment income  $557,375   $2,529,843   $36,954   $122,134 
                     
** Shares of Common Stock Issued (no par value)                    
Shares sold   250,000    1,600,000    50,000    150,000 
Shares redeemed   (1,950,000)   (1,450,000)       (200,000)
Net increase (decrease)   (1,700,000)   150,000    50,000    (50,000)

 

See Notes to Financial Statements

24

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   Gaming ETF   Generic Drugs ETF   Pharmaceutical ETF 
   For the Period   For the Year   For the Period   For the Year   For the Period   For the Year 
   Ended   Ended   Ended   Ended   Ended   Ended 
   March 31,   September 30,   March 31,   September 30,   March 31,   September 30, 
   2018   2017   2018   2017   2018   2017 
   (unaudited)       (unaudited)       (unaudited)     
                               
Operations:                              
Net investment income (loss)  $440,417   $678,799   $(2,241)  $16,273   $2,438,650   $6,048,603 
Net realized gain   498,729    1,103,183    53,160    67,042    19,752,107    7,980,033 
Net change in unrealized appreciation (depreciation)   1,990,626    2,501,573    310,560    (106,625)   (20,076,520)   1,765,322 
Net increase (decrease) in net assets resulting from operations   2,929,772    4,283,555    361,479    (23,310)   2,114,237    15,793,958 
                               
Dividends to shareholders:                              
Dividends from net investment income   (700,050)   (586,300)   (55,050)   (19,400)   (1,824,549)   (5,854,105)
                               
Share transactions:**                              
Proceeds from sale of shares   32,117,050    14,154,237        4,333,286    319,496,500    786,410,157 
Cost of shares redeemed   (4,691,937)   (14,296,884)       (3,365,817)   (359,090,305)   (743,098,245)
Increase (Decrease) in net assets resulting from share transactions   27,425,113    (142,647)       967,469    (39,593,805)   43,311,912 
Total increase (decrease) in net assets   29,654,835    3,554,608    306,429    924,759    (39,304,117)   53,251,765 
Net Assets, beginning of period   23,435,688    19,881,080    3,360,859    2,436,100    285,189,976    231,938,211 
Net Assets, end of period†  $53,090,523   $23,435,688   $3,667,288   $3,360,859   $245,885,859   $285,189,976 
† Including undistributed (accumulated) net investment income (loss)  $345,277   $604,910   $(36,778)  $20,513   $1,681,200   $1,067,099 
                               
** Shares of Common Stock Issued (no par value)                              
Shares sold   700,000    350,000        200,000    5,450,000    14,500,000 
Shares redeemed   (100,000)   (350,000)       (150,000)   (6,050,000)   (13,600,000)
Net increase (decrease)   600,000            50,000    (600,000)   900,000 

 

See Notes to Financial Statements

25

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   Retail ETF   Semiconductor ETF 
   For the Period   For the Year   For the Period   For the Year 
   Ended   Ended   Ended   Ended 
   March 31,   September 30,   March 31,   September 30, 
   2018   2017   2018   2017 
   (unaudited)       (unaudited)     
                     
Operations:                    
Net investment income  $375,997   $1,177,871   $3,902,145   $9,564,945 
Net realized gain   4,839,737    182,469    201,634,518    221,347,767 
Net change in unrealized appreciation (depreciation)   3,136,221    2,134,169    (85,649,002)   (6,994,961)
Net increase in net assets resulting from operations   8,351,955    3,494,509    119,887,661    223,917,751 
                     
Dividends to shareholders:                    
Dividends from net investment income   (1,030,346)   (1,772,514)   (10,499,228)   (4,764,060)
                     
Share transactions:**                    
Proceeds from sale of shares   46,104,387    32,054,970    7,660,077,499    10,938,048,365 
Cost of shares redeemed   (44,927,797)   (93,737,069)   (7,497,814,912)   (10,934,279,639)
Increase (Decrease) in net assets resulting from share transactions   1,176,590    (61,682,099)   162,262,587    3,768,726 
Total increase (decrease) in net assets   8,498,199    (59,960,104)   271,651,020    222,922,417 
Net Assets, beginning of period   58,746,284    118,706,388    800,052,657    577,130,240 
Net Assets, end of period†  $67,244,483   $58,746,284   $1,071,703,677   $800,052,657 
† Including undistributed net investment income  $196,912   $851,261   $903,403   $7,500,486 
                     
** Shares of Common Stock Issued (no par value)                    
Shares sold   500,000    400,000    74,750,000    137,800,000 
Shares redeemed   (500,000)   (1,200,000)   (73,050,000)   (137,550,000)
Net increase (decrease)       (800,000)   1,700,000    250,000 

 

See Notes to Financial Statements

26

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Biotech ETF
   For the                    
   Six Months                    
   Ended                    
   March 31,  For the Year Ended September 30,
   2018  2017    2016    2015    2014  2013
   (unaudited)                    
Net asset value, beginning of period      $134.17    $115.25     $114.45    $105.84    $  82.74   $54.07 
Income from investment operations:                                
Net investment income (loss)     0.27(a)   0.58(a)   0.33    0.24    (0.03)   0.01 
Net realized and unrealized gain (loss) on investments     (13.47)   18.67    0.81    8.37    23.13    28.85 
Total from investment operations     (13.20)   19.25    1.14    8.61    23.10    28.86 
Less:                                
Dividends from net investment income     (0.68)   (0.33)   (0.34)       (f)   (0.02)
Distributions from net realized capital gains                         (0.17)
Total dividends and distributions     (0.68)   (0.33)   (0.34)           (0.19)
Net asset value, end of period    $120.29   $134.17   $115.25   $114.45   $105.84     $82.74 
Total return (b)     (9.86)%(c)   16.77%   0.97%   8.13%   27.92%   53.55%
 
 
Ratios/Supplemental Data                                
Net assets, end of period (000’s)  $438,652 $717,330 $598,914 $651,978 $539,423 $434,089 
Ratio of gross expenses to average net assets     0.39%(d)   0.39%   0.40%   0.40%   0.41%   0.41%
Ratio of net expenses to average net assets     0.35%(d)   0.35%   0.35%   0.35%   0.35%   0.35%
Ratio of net expenses to average net assets excluding interest expense     0.35%(d)   0.35%   0.35%   0.35%   0.35%   0.35%
Ratio of net investment income (loss) to average net assets     0.43%(d)   0.48%   0.29%   0.18%   (0.03)%   0.01%
Portfolio turnover rate (e)     14%(c)   27%   41%   12%   11%   0%
   Environmental Services ETF
   For the                    
   Six Months                    
   Ended                    
   March 31,  For the Year Ended September 30,
   2018  2017    2016    2015    2014  2013
   (unaudited)                         
Net asset value, beginning of period    $86.02   $69.68   $58.37   $64.57   $62.43   $49.65 
Income from investment operations:                                
Net investment income     0.33(a)   0.66(a)   0.63    0.73    1.00    0.91 
Net realized and unrealized gain (loss) on investments     (0.70)   16.21    11.36    (5.88)   1.89    12.66 
Total from investment operations     (0.37)   16.87    11.99    (5.15)   2.89    13.57 
Less:                                
Dividends from net investment income     (0.78)   (0.53)   (0.68)   (1.05)   (0.75)   (0.79)
Net asset value, end of period    $84.87   $86.02   $69.68   $58.37   $64.57   $62.43 
Total return (b)     (0.45)%(c)   24.31%   20.75%   (8.18)%   4.62%   27.67%
                                 
                                 
Ratios/Supplemental Data                                
Net assets, end of period (000’s)  $21,217 $17,204 $17,420 $14,593 $16,142 $18,729 
Ratio of gross expenses to average net assets     1.01%(d)   0.95%   0.93%   1.15%   0.92%   1.01%
Ratio of net expenses to average net assets     0.56%(d)   0.55%   0.55%   0.55%   0.55%   0.55%
Ratio of net expenses to average net assets excluding interest expense     0.55%(d)   0.55%   0.55%   0.55%   0.55%   0.55%
Ratio of net investment income to average net assets     0.77%(d)   0.86%   1.00%   1.15%   1.32%   1.60%
Portfolio turnover rate (e)     12%(c)   20%   40%   19%   13%   5%
 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Not Annualized
(d) Annualized
(e) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(f) Amount represents less than $0.005 per share

 

See Notes to Financial Statements

27

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Gaming ETF
   For the                    
   Six Months                    
   Ended                    
   March 31,  For the Year Ended September 30,
   2018  2017    2016    2015    2014  2013
   (unaudited)                         
Net asset value, beginning of period     $42.61    $36.15    $29.82    $43.38    $47.49    $34.22 
Income from investment operations:                                
Net investment income     0.47(a)   1.13(a)   0.94(a)   1.12(a)   1.76    1.10 
Net realized and unrealized gain (loss) on investments     4.17    6.40    6.69    (12.80)   (5.35)   13.55 
Total from investment operations     4.64    7.53    7.63    (11.68)   (3.59)   14.65 
Less:                                
Dividends from net investment income     (1.08)   (1.07)   (1.30)   (1.88)   (0.52)   (1.38)
Net asset value, end of period    $46.17   $42.61   $36.15   $29.82   $43.38   $47.49 
Total return (b)     10.89%(c)   21.58%   26.23%  (27.91)%   (7.76)%   44.14%
 
 
Ratios/Supplemental Data                                
Net assets, end of period (000’s)  $53,091 $23,436 $19,881 $23,859 $43,384 $56,982 
Ratio of gross expenses to average net assets     0.77%(d)   0.94%   0.93%   1.00%   0.73%   0.83%
Ratio of net expenses to average net assets     0.65%(d)   0.65%   0.67%   0.66%   0.65%   0.65%
Ratio of net expenses to average net assets excluding interest expense     0.65%(d)   0.65%   0.65%   0.65%   0.65%   0.65%
Ratio of net investment income to average net assets     2.03%(d)   2.97%   2.88%   2.92%   2.73%   2.73%
Portfolio turnover rate (e)     16%(c)   22%   29%   27%   35%   16%

 

 Generic Drugs ETF  
       For the Period  
 For the Six     January 12,  
 Months  For the Year  2016 (f)  
 Ended  Ended  through  
 March 31,  September 30,  September 30,  
 2018  2017  2016  
 (unaudited)          
Net asset value, beginning of period  $22.41         $24.36     $25.21   
Income from investment operations:                     
Net investment income (loss)   (0.01)(a)     0.09(a)     0.07   
Net realized and unrealized gain (loss) on investments   2.42      (1.94)     (0.92)  
Total from investment operations   2.41      (1.85)     (0.85)  
Less:                     
Dividends from net investment income   (0.37)     (0.10)        
Net asset value, end of period  $24.45     $22.41     $24.36   
Total return (b)   10.78%(c)     (7.58)%     (3.37)%(c)  
                      
                      
Ratios/Supplemental Data                     
Net assets, end of period (000’s)  $3,667     $3,361     $2,436   
Ratio of gross expenses to average net assets   3.52%(d)     2.94%     5.70%(d)  
Ratio of net expenses to average net assets   0.55%(d)     0.57%     0.55%(d)  
Ratio of net expenses to average net assets excluding interest expense   0.55%(d)     0.55%     0.55%(d)  
Ratio of net investment income (loss) to average net assets   (0.12)%(d)     0.40%     0.39%(d)  
Portfolio turnover rate (e)   3%(c)     61%     47%(c)  
 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Not Annualized
(d) Annualized
(e) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(f) Commencement of operations

 

See Notes to Financial Statements

28

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Pharmaceutical ETF
   For the                    
   Six Months                    
   Ended                    
   March 31,  For the Year Ended September 30,
   2018  2017    2016    2015    2014  2013
   (unaudited)                    
Net asset value, beginning of period       $57.75      $57.44      $63.01       $63.54      $47.89      $41.03 
Income from investment operations:                                
Net investment income     0.53(a)   1.18(a)   1.24(a)   1.31    1.02    1.08 
Net realized and unrealized gain (loss) on investments     (1.23)   0.26    (5.41)   (0.62)   15.66    7.78 
Total from investment operations     (0.70)   1.44    (4.17)   0.69    16.68    8.86 
Less:                                
Dividends from net investment income     (0.37)   (1.13)   (1.40)   (1.22)   (1.03)   (2.00)
Net asset value, end of period    $56.68   $57.75   $57.44   $63.01   $63.54   $47.89 
Total return (b)     (1.24)%(c)   2.59%   (6.72)%   0.96%   35.19%   22.44%
                                 
                                 
Ratios/Supplemental Data                                
Net assets, end of period (000’s)  $245,886 $285,190 $231,938 $314,297 $405,888 $241,267 
Ratio of gross expenses to average net assets     0.41%(d)   0.40%   0.41%   0.41%   0.42%   0.43%
Ratio of net expenses to average net assets     0.36%(d)   0.35%   0.35%   0.36%   0.35%   0.35%
Ratio of net expenses to average net assets excluding interest expense     0.35%(d)   0.35%   0.35%   0.35%   0.35%   0.35%
Ratio of net investment income to average net assets     1.80%(d)   2.14%   2.04%   1.78%   1.85%   2.30%
Portfolio turnover rate (e)     9%(c)   40%   25%   12%   14%   3%
   Retail ETF
   For the                         
   Six Months                         
   Ended                         
   March 31,  For the Year Ended September 30,
   2018  2017    2016    2015    2014  2013
   (unaudited)                       
Net asset value, beginning of period    $81.42   $78.02   $73.57   $62.27   $55.34   $44.88 
Income from investment operations:                                
Net investment income     0.54(a)   1.15(a)   0.93(a)   1.12(a)   0.60    0.27 
Net realized and unrealized gain on investments     12.67    3.64    5.27    10.47    6.94    11.04 
Total from investment operations     13.21    4.79    6.20    11.59    7.54    11.31 
Less:                                
Dividends from net investment income     (1.43)   (1.39)   (1.75)   (0.29)   (0.61)   (0.85)
Net asset value, end of period    $93.20   $81.42   $78.02   $73.57   $62.27   $55.34 
Total return (b)     16.26%(c)   6.25%   8.42%   18.63%   13.65%   25.69%
                                 
                                 
Ratios/Supplemental Data                                
Net assets, end of period (000’s)  $67,244 $58,746 $118,706 $203,909 $66,724 $42,696 
Ratio of gross expenses to average net assets     0.55%(d)   0.50%   0.43%   0.42%   0.63%   0.69%
Ratio of net expenses to average net assets     0.35%(d)   0.35%   0.35%   0.35%   0.35%   0.35%
Ratio of net expenses to average net assets excluding interest expense     0.35%(d)   0.35%   0.35%   0.35%   0.35%   0.35%
Ratio of net investment income to average net assets     1.19%(d)   1.46%   1.22%   1.49%   1.23%   1.84%
Portfolio turnover rate (e)     14%(c)   17%   9%   5%   3%   3%
 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Not Annualized
(d) Annualized
(e) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.

 

See Notes to Financial Statements

29

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Semiconductor ETF
   For the                    
   Six Months                    
   Ended                    
   March 31,  For the Year Ended September 30,
   2018  2017    2016    2015    2014  2013
   (unaudited)                    
Net asset value, beginning of period        $93.34      $69.36      $49.97      $51.10       $39.88      $31.66 
Income from investment operations:                                
Net investment income     0.34(a)   1.10(a)   0.82(a)   1.08(a)   0.62    0.72 
Net realized and unrealized gain (loss) on investments     12.06    23.46    19.67    (1.58)   11.26    8.20 
Payment from Adviser             0.04(f)            
Total from investment operations     12.40    24.56    20.53    (0.50)   11.88    8.92 
Less:                                
Dividends from net investment income     (1.40)   (0.58)   (1.14)   (0.63)   (0.66)   (0.70)
Net asset value, end of period    $104.34   $93.34   $69.36   $49.97   $51.10   $39.88 
Total return (b)     13.36%(c)   35.63%   41.73%   (1.09)%   30.13%   28.70%
                                 
                                 
Ratios/Supplemental Data                                
Net assets, end of period (000’s)  $1,071,704 $800,053 $577,130 $190,923 $414,959 $262,017 
Ratio of gross expenses to average net assets     0.37%(d)   0.38%   0.41%   0.41%   0.41%   0.43%
Ratio of net expenses to average net assets     0.35%(d)   0.35%   0.36%   0.35%   0.35%   0.35%
Ratio of net expenses to average net assets excluding interest expense     0.35%(d)   0.35%   0.35%   0.35%   0.35%   0.35%
Ratio of net investment income to average net assets     0.66%(d)   1.38%   1.45%   2.01%   1.68%   1.81%
Portfolio turnover rate (e)     7%(c)   22%   53%   18%   9%   4%
 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Not Annualized
(d) Annualized
(e) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(f) 0.06% of total return, representing $0.04 per share, consisted of a payment by the Adviser (See Note 3).

 

See Notes to Financial Statements

30

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

March 31, 2018 (unaudited)

 

Note 1—Fund Organization—VanEck Vectors ETF Trust (the “Trust”) is registered under the Investment Company Act of 1940, as amended, as an open-end management investment company. The Trust was incorporated in Delaware as a statutory trust on March 15, 2001. The Trust operates as a series fund, and as of March 31, 2018, offers fifty-six investment portfolios, each of which represents a separate series of the Trust.

 

These financial statements relate only to the following investment portfolios: Biotech ETF, Environmental Services ETF, Gaming ETF, Generic Drugs ETF, Pharmaceutical ETF, Retail ETF and Semiconductor ETF (each a “Fund” and, together, the “Funds”). Each Fund was created to provide investors with the opportunity to purchase a security representing a proportionate undivided interest in a portfolio of securities consisting of substantially all of the common stocks in substantially the same weighting, in an index published by Indxx LLC, ICE Data Indices, LLC or MV Index Solutions GmbH (“MVIS”), a wholly owned subsidiary of Van Eck Associates Corporation (the “Adviser”).

 

The Funds’ respective indices are presented below:

 

Fund Index
Biotech ETF MVIS® US Listed Biotech 25 Index*
Environmental Services ETF NYSE Arca Environmental Services Index
Gaming ETF MVIS® Global Gaming Index*
Generic Drugs ETF Indxx Global Generics & New Pharma Index
Pharmaceutical ETF MVIS® US Listed Pharmaceutical 25 Index*
Retail ETF MVIS® US Listed Retail 25 Index*
Semiconductor ETF MVIS® US Listed Semiconductor 25 Index*

 

* Published by MV Index Solutions GmbH

 

Note 2—Significant Accounting Policies—The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.

 

The Funds are investment companies and are following accounting and reporting requirements of Accounting Standards Codification (“ASC”) 946 Financial Services — Investment Companies.

 

The following is a summary of significant accounting policies followed by the Funds.

 

A.Security Valuation—The Funds value their investments in securities and other assets and liabilities at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Securities traded on national exchanges or traded on the NASDAQ National Market System are valued at the last sales price as reported at the close of each business day. Securities traded on the NASDAQ Stock Market are valued at the NASDAQ official closing price. Over-the-counter securities not included in the NASDAQ National Market System and listed securities for which no sale was reported are valued at the mean of the bid and ask prices. To the extent these securities are actively traded they are categorized as Level 1 in the fair value hierarchy (as described below). Certain foreign securities, whose values may be affected by market direction or events occurring before the Funds’ pricing time (4:00 p.m. Eastern Time) but after the last close of the securities’ primary market, are fair valued using a pricing service and are categorized as Level 2 in the fair value hierarchy. The pricing service, using methods approved by the Board of Trustees, considers the correlation of the trading patterns of the foreign security to intraday trading in the U.S. markets, based on indices of domestic securities and other appropriate indicators such as prices of relevant ADR’s and futures contracts. The Funds may also fair value securities in other situations, such as, when a particular foreign market is closed but the Fund is open. Short-term debt securities with sixty days or less to maturity are valued at amortized cost, which with accrued interest approximates fair value. Money market fund investments are valued at net asset value and are considered to be Level 1 in the fair value hierarchy. The Pricing Committee of the Adviser provides oversight of the Funds’ valuation policies and procedures, which are approved by the Funds’ Board of Trustees. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities dealers, and other market sources to determine fair value. The Pricing Committee convenes regularly to review the fair value of financial instruments or other assets. If market quotations for a security or other asset are not readily available, or if the Adviser believes it does not otherwise reflect the fair value of a security or asset, the security or asset will be fair valued by the Pricing Committee in accordance with the Funds’ valuation policies and
31

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(unaudited) (continued)

 

procedures. The Pricing Committee employs various methods for calibrating the valuation approaches utilized to determine fair value, including a regular review of key inputs and assumptions, periodic comparisons to valuations provided by other independent pricing services, transactional back-testing and disposition analysis.

 

Certain factors such as economic conditions, political events, market trends, the nature of and duration of any restrictions on disposition, trading in similar securities of the issuer or comparable issuers and other security specific information are used to determine the fair value of these securities. Depending on the relative significance of valuation inputs, these securities may be classified either as Level 2 or Level 3 in the fair value hierarchy. The price which the Funds may realize upon sale of an investment may differ materially from the value presented in the Schedules of Investments.

 

The Funds utilize various methods to measure the fair value of their investments on a recurring basis, which includes a hierarchy that prioritizes inputs to valuation methods used to measure fair value. The fair value hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The transfers between levels of the fair value hierarchy assume the financial instruments where transferred at the beginning of the reporting period. The three levels of the fair value hierarchy are described below:

 

Level 1 – Quoted prices in active markets for identical securities.

 

Level 2 – Significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

 

Level 3 – Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).

 

A summary of the inputs, the levels used to value the Funds’ investments, and transfers between levels are located in the Schedules of Investments. Additionally, tables that reconcile the valuation of the Funds’ Level 3 investments and that present additional information about valuation methodologies and unobservable inputs, if applicable, are located in the Schedules of Investments.

 

B.Federal Income Taxes—It is each Fund’s policy to comply with the provisions of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Therefore, no federal income tax provision is required.

 

C.Dividends and Distributions to Shareholders—Dividends to shareholders from net investment income and distributions from net realized capital gains, if any, are declared and paid annually by each Fund (except for dividends from net investment income on Pharmaceutical ETF, which are declared and paid quarterly). Income dividends and capital gain distributions are determined in accordance with U.S. income tax regulations, which may differ from such amounts determined in accordance with GAAP.

 

D.Currency Translation—Assets and liabilities denominated in foreign currencies and commitments under foreign currency contracts are translated into U.S. dollars at the closing prices of such currencies each business day as quoted by one or more sources. Purchases and sales of investments are translated at the exchange rates prevailing when such investments are acquired or sold. Foreign denominated income and expenses are translated at the exchange rates prevailing when accrued. The portion of realized and unrealized gains and losses on investments that result from fluctuations in foreign currency exchange rates is not separately disclosed in the financial statements. Recognized gains or losses attributable to foreign currency fluctuations on foreign currency denominated assets, other than investments, and liabilities are recorded as net realized gain (loss) on foreign currency transactions and foreign denominated assets and liabilities in the Statements of Operations.

 

E.Restricted Securities—The Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities, if any, is included at the end of each Fund’s Schedule of Investments.
32

 

 

F.Repurchase Agreements—The Funds may enter into repurchase agreements with financial institutions, deemed to be creditworthy by the Adviser, to generate income from their excess cash balances and to invest securities lending cash collateral. A repurchase agreement is an agreement under which a Fund acquires securities from a seller, subject to resale to the seller at an agreed upon price and date. A Fund, through its custodian/securities lending agent, takes possession of securities collateralizing the repurchase agreement. Pursuant to the terms of the repurchase agreement, such securities must have an aggregate market value greater than or equal to the terms of the repurchase price plus accrued interest at all times. If the value of the underlying securities falls below the value of the repurchase price plus accrued interest, the Funds will require the seller to deposit additional collateral by the next business day. If the request for additional collateral is not met, or the seller defaults on its repurchase obligation, the Funds maintain their right to sell the underlying securities at market value and may claim any resulting loss against the seller. Repurchase agreements held as of March 31, 2018 are reflected in the Schedules of Investments.

 

G.Offsetting Assets and Liabilities—In the ordinary course of business, the Funds enter into transactions subject to enforceable master netting or other similar agreements. Generally, the right of setoff in those agreements allows the Funds to set off any exposure to a specific counterparty with any collateral received or delivered to that counterparty based on the terms of the agreements. The Funds may pledge or receive cash and/or securities as collateral for derivative instruments, securities lending and repurchase agreements. For financial reporting purposes, the Funds present securities lending and repurchase agreement assets and liabilities on a gross basis in the Statements of Assets and Liabilities. Collateral held at March 31, 2018 is presented in the Schedules of Investments. Refer to related disclosures in Note 2F (Repurchase Agreements) and Note 9 (Securities Lending).

 

H.Other—Security transactions are accounted for on trade date. Realized gains and losses are determined based on the specific identification method. Dividend income is recorded on the ex-dividend date except that certain dividends from foreign securities are recognized upon notification of the ex-dividend date. Interest income, including amortization of premiums and discounts, is accrued as earned.

 

In the normal course of business, the Funds enter into contracts that contain a variety of general indemnifications. The Funds’ maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Funds that have not yet occurred. However, the Adviser believes the risk of loss under these arrangements to be remote.

 

Note 3—Investment Management and Other Agreements—The Adviser is the investment adviser to the Funds. The Adviser receives a management fee, calculated daily and payable monthly based on an annual rate of each Fund’s average daily net assets. The Adviser has agreed, until at least February 1, 2019, to waive management fees and assume expenses to prevent each Fund’s total annual operating expenses (excluding acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses) from exceeding the expense limitations listed in the table below. Refer to the Statements of Operations for the amounts waived/assumed by the Adviser for the period ended March 31, 2018.

 

The current expense limitations and management fee rates are as follows:

 

Fund  Expense
Limitations
  Management
Fee Rates
Biotech ETF   0.35%   0.35%
Environmental Services ETF   0.55    0.50 
Gaming ETF   0.65    0.50 
Generic Drugs ETF   0.55    0.50 
Pharmaceutical ETF   0.35    0.35 
Retail ETF   0.35    0.35 
Semiconductor ETF   0.35    0.35 

 

During the year ended September 30, 2016, the Adviser voluntarily reimbursed the Semiconductor ETF $340,000 for transactional losses. The per share and total return impact to the Fund is reflected in the Financial Highlights.

 

In addition, Van Eck Securities Corporation (the “Distributor”), an affiliate of the Adviser, acts as the Funds’ distributor. Certain officers and a Trustee of the Trust are officers, directors or stockholders of the Adviser and Distributor.

33

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(unaudited) (continued)

 

Note 4—Investments—For the period ended March 31, 2018, the cost of purchases and proceeds from sales of investments other than U.S. government obligations and short-term obligations (excluding in-kind transactions described in Note 6) were as follows:

 

Fund  Cost of Investments
 Purchased
  Proceeds from
 Investments Sold
Biotech ETF  $84,113,285   $85,729,913 
Environmental Services ETF   2,210,087    2,304,141 
Gaming ETF   8,584,537    7,022,826 
Generic Drugs ETF   121,705    166,994 
Pharmaceutical ETF   23,128,123    23,179,553 
Retail ETF   9,065,529    9,538,423 
Semiconductor ETF   73,211,942    88,145,753 

 

Note 5—Income Taxes—As of March 31, 2018, for Federal income tax purposes, the identified cost of investments owned, net unrealized appreciation (depreciation), gross unrealized appreciation, and gross unrealized depreciation of investments were as follows:

 

Fund  Cost of Investments  Gross Unrealized
Appreciation
  Gross Unrealized
Depreciation
  Net Unrealized
Appreciation
(Depreciation)
Biotech ETF  $  512,008,932   $21,014,142   $(92,326,954)  $(71,312,812)
Environmental Services ETF   21,236,080    2,383,933    (645,451)   1,738,482 
Gaming ETF   54,907,405    3,931,558    (3,483,928)   447,630 
Generic Drugs ETF   3,761,677    756,826    (632,546)   124,280 
Pharmaceutical ETF   354,242,100    1,465,825    (81,900,330)   (80,434,505)
Retail ETF   72,302,254    3,258,660    (8,244,136)   (4,985,476)
Semiconductor ETF   1,190,728,493    896,749    (90,633,782)   (89,737,033)

 

The tax character of dividends paid to shareholders during the year ended September 30, 2017 was as follows:

 

Fund  Ordinary Income
Biotech ETF  $1,715,606 
Environmental Services ETF   132,750 
Gaming ETF   586,300 
Generic Drugs ETF   19,400 
Pharmaceutical ETF   5,854,105 
Retail ETF   1,772,514 
Semiconductor ETF   4,764,060 

 

The tax character of current year distributions will be determined at the end of the current fiscal year.

 

At September 30, 2017, the Funds had capital loss carryforwards available to offset future capital gains, as follows:

 

Fund  Short-Term
Capital Losses
with No Expiration
  Long-Term
Capital Losses
with No Expiration
  Amount
Expiring in
the Year Ended
September 30, 2018
  Total
Biotech ETF  $   $(11,474,284)  $   $(11,474,284)
Environmental Services ETF   (539,614)   (5,764,706)   (479,375)   (6,783,695)
Gaming ETF   (2,187,113)   (3,941,930)       (6,129,043)
Generic Drugs ETF   (120,655)   (80,087)       (200,742)
Pharmaceutical ETF   (5,362,815)   (6,716,207)       (12,079,022)
Retail ETF   (1,336,686)   (1,417,095)       (2,753,781)
Semiconductor ETF   (1,648,128)   (425,995)       (2,074,123)

 

The Funds recognize the tax benefits of uncertain tax positions only where the position is “more-likely-than-not” to be sustained assuming examination by applicable tax authorities. Management has analyzed the Funds’ tax positions, and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on return filings for all open tax years. The Funds do not have exposure for additional years that might still be open in

34

 

 

certain foreign jurisdictions. Therefore, no provision for income tax is required in the Funds’ financial statements. However, certain Funds are subject to foreign taxes on the appreciation in value of certain investments. The Funds provide for such taxes on both realized and unrealized appreciation.

 

The Funds recognize interest and penalties, if any, related to uncertain tax positions as income tax expense in the Statements of Operations. During the period ended March 31, 2018, the Funds did not incur any interest or penalties.

 

Note 6—Capital Share Transactions—As of March 31, 2018, there was an unlimited number of capital shares of beneficial interest authorized by the Trust with no par value. Fund shares are not individually redeemable and are issued and redeemed at their net asset value per share only through certain authorized broker-dealers (“Authorized Participants”) in blocks of shares (“Creation Units”), consisting of 50,000 shares, or multiples thereof.

 

The consideration for the purchase or redemption of Creation Units of the Funds generally consists of the in-kind contribution or distribution of securities constituting the Funds’ underlying index (“Deposit Securities”) plus a balancing cash component to equate the transaction to the net asset value per share of the Fund on the transaction date. Cash may also be substituted in an amount equivalent to the value of certain Deposit Securities, generally as a result of market circumstances, or when the securities are not available in sufficient quantity for delivery or are not eligible for trading by the Authorized Participant. The Funds may issue Creation Units in advance of receipt of Deposit Securities subject to various conditions, including a requirement to maintain on deposit at the Custodian for the benefit of the Funds, collateral consisting of cash in the form of U.S. dollars at least equal to 115% of the daily marked to market value of the missing Deposit Securities.

 

Authorized Participants purchasing and redeeming Creation Units may pay transaction fees directly to The Bank of New York Mellon. In addition, the Funds may impose certain variable fees for creations and redemptions with respect to transactions in Creation Units for cash, or on transactions effected outside the clearing process, which are treated as increases in capital. These variable fees, if any, are reflected in share transactions in the Statements of Changes in Net Assets.

 

For the period ended March 31, 2018, the Funds had in-kind contributions and redemptions as follows:

 

Fund  In-Kind Contributions  In-Kind Redemptions
Biotech ETF  $32,368,213   $247,868,615 
Environmental Services ETF   4,289,265     
Gaming ETF   30,073,511    4,417,017 
Pharmaceutical ETF   319,515,272    359,084,634 
Retail ETF   45,894,807    44,900,506 
Semiconductor ETF   7,666,956,464    7,497,866,780 

 

The in-kind contributions and in-kind redemptions in this table represent the accumulation of each Fund’s daily net shareholder transactions including rebalancing activity, while the Statements of Changes in Net Assets reflect gross shareholder transactions including any cash component of the transactions.

 

Note 7—Concentration of Risk—The investment objective of each Fund is to seek investment results that correspond generally to the price and yield performance, before fees and expenses, of its underlying index, as indicated in the name of each Fund. The Adviser uses a “passive” or index approach to achieve each Fund’s investment objective by investing in a portfolio of securities that generally replicates the Fund’s index. Each of the Funds is classified as a non-diversified fund under the 1940 Act. Non-diversified funds generally hold securities of fewer issuers than diversified funds and may be more susceptible to the risks associated with these particular issuers, or to a single economic, political or regulatory occurrences affecting these issuers. The Funds may purchase securities on foreign exchanges. Securities of foreign issuers involve special risks and considerations not typically associated with investing in U.S. issuers. These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.

 

In March 2017, the United Kingdom triggered Article 50, and is now scheduled to leave the European Union (“EU”) by the end of March 2019. Significant uncertainty exists on how the withdrawal will take place, the terms of the withdrawal

35

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)

 

and the effects such withdrawal will have on the EU and the United Kingdom. This may further impact the value of the Euro and the British pound sterling, and has caused volatility and uncertainty in European and global markets.

 

A more complete description of risks is included in each Fund’s Prospectus and Statement of Additional Information.

 

Note 8—Trustee Deferred Compensation Plan—The Trust has a Deferred Compensation Plan (the “Plan”) for Trustees under which the Trustees can elect to defer receipt of their trustee fees until retirement, disability or termination from the Board of Trustees. The fees otherwise payable to the participating Trustees are deemed invested in shares of the Funds as directed by the Trustees.

 

The expense for the Plan is included in “Trustees’ fees and expenses” in the Statements of Operations. The liability for the Plan is shown as “Deferred Trustee fees” in the Statements of Assets and Liabilities.

 

Note 9—Securities Lending—To generate additional income, each of the Funds may lend its securities pursuant to a securities lending agreement with The Bank of New York Mellon, the securities lending agent and also the Funds’ custodian. Each Fund may lend up to 33% of its investments requiring that the loan be continuously collateralized by cash, U.S. government or U.S. government agency securities, shares of an investment trust or mutual fund, or any combination of cash and such securities at all times equal to at least 102% (105% for foreign securities) of the market value plus accrued interest on the securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled on the next business day. During the term of the loan, the Funds will continue to receive any dividends, interest or amounts equivalent thereto on the securities loaned, while receiving a fee from the borrower and/or earning interest on the investment of the cash collateral. Such fees and interest are shared with the securities lending agent under the terms of the securities lending agreement. The Funds may pay reasonable finders’, administrative and custodial fees in connection with a loan of its securities. Securities lending income is disclosed as such in the Statements of Operations. The collateral for securities loaned is recognized in the Schedules of Investments and the Statements of Assets and Liabilities. The cash collateral is maintained on the Funds’ behalf by the lending agent and is invested in repurchase agreements collateralized by obligations of the U.S. Treasury and/or Government Agencies. Loans are subject to termination at the option of the borrower or the Funds. Upon termination of the loan, the borrower will return to the lender securities identical to the securities loaned. The Funds bear the risk of delay in recovery of, or even loss of rights in, the securities loaned should the borrower of the securities fail financially. The value of loaned securities and related collateral outstanding at March 31, 2018 are presented on a gross basis in the Schedules of Investments and Statements of Assets and Liabilities.

 

The following table presents repurchase agreements held as collateral by type of security on loan pledged as of March 31, 2018:

 

   Gross Amount of Recognized
Liabilities for Securities Loaned
in the Statements of Assets
and Liabilities*
Fund  Equity Securities
Biotech ETF   1,542,625 
Environmental Services ETF   1,704,843 
Gaming ETF   2,239,962 
Generic Drugs ETF   170,345 
Pharmaceutical ETF   28,827,206 
Semiconductor ETF   29,090,395 

 

* Remaining contractual maturity of the agreements: overnight and continuous
36

 

 

Note 10—Bank Line of Credit—The Funds may participate in a $200 million committed credit facility (the “Facility”) to be utilized for temporary financing until the settlement of sales or purchases of portfolio securities, the repurchase or redemption of shares of the Funds and other temporary or emergency purposes. The Funds have agreed to pay commitment fees, pro rata, based on the unused but available balance. Interest is charged to the Funds at rates based on prevailing market rates in effect at the time of borrowings. During the period ended March 31, 2018, the following Funds borrowed under this Facility:

 

Fund  Days
Outstanding
  Average Daily
Loan Balance
  Average
Interest Rate
  Outstanding Loan
Balance as of
March 31, 2018
Biotech ETF   54   $1,216,810    2.69%  $455,842 
Gaming ETF   52    154,834    2.87    146,004 
Pharmaceutical ETF   127    696,070    2.68     
Retail ETF   52    133,110    2.69    72,801 
Semiconductor ETF   147    1,991,734    2.69     

 

Note 11—Custodian Fees—The Funds have entered into an expense offset agreement with the custodian wherein they receive a credit toward the reduction of custodian fees whenever there are uninvested cash balances. The Funds could have invested their cash balances elsewhere if they had not agreed to a reduction in fees under the expense offset agreement with the custodian. For the period ended March 31, 2018, there were offsets to custodian fees and these amounts are reflected in custody expense in the Statements of Operations.

 

Note 12—Subsequent Events—The Funds have evaluated events and transactions for potential recognition or disclosure through the date the financial statements were issued.

37

 

This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by a VanEck Vectors ETF Trust (the “Trust”) Prospectus, which includes more complete information. An investor should consider the investment objective, risks, and charges and expenses of the Funds carefully before investing. The prospectus contains this and other information about the investment company. Please read the prospectus carefully before investing.

 

Additional information about the Trust’s Board of Trustees/Officers and a description of the policies and procedures the Trust uses to determine how to vote proxies relating to portfolio securities are provided in the Statement of Additional Information. The Statement of Additional Information and information regarding how the Trust voted proxies relating to portfolio securities during the most recent twelve month period ending June 30 is available, without charge, by calling 800.826.2333, or by visiting vaneck.com, or on the Securities and Exchange Commission’s website at http://www.sec.gov.

 

The Trust files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Trust’s Form N-Qs are available on the Commission’s website at http://www.sec.gov and may be reviewed and copied at the Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 202.942.8090. The Funds’ complete schedules of portfolio holdings are also available by calling 800.826.2333 or by visiting vaneck.com.

 

 

Investment Adviser: Van Eck Associates Corporation  
Distributor: Van Eck Securities Corporation
666 Third Avenue, New York, NY 10017
vaneck.com
 
Account Assistance: 800.826.2333 INDUSSAR
 
  SEMI-ANNUAL REPORT
March 31, 2018
(unaudited)

 

VANECK VECTORS®  
   
Morningstar International Moat ETF MOTI®
   
Morningstar Wide Moat ETF MOAT®
   
NDR CMG Long/Flat Allocation ETF LFEQTM
   
Spin-Off ETF SPUN®

 

     
  800.826.2333 vaneck.com
 

 

 

President’s Letter 1
Management Discussion 4
Explanation of Expenses 5
Schedule of Investments  
Morningstar International Moat ETF 6
Morningstar Wide Moat ETF 9
NDR CMG Long/Flat Allocation ETF 11
Spin-Off ETF 12
Statements of Assets and Liabilities  
Morningstar International Moat ETF 16
Morningstar Wide Moat ETF 16
NDR CMG Long/Flat Allocation ETF 16
Spin-Off ETF 16
Statements of Operations  
Morningstar International Moat ETF 17
Morningstar Wide Moat ETF 17
NDR CMG Long/Flat Allocation ETF 17
Spin-Off ETF 17
Statements of Changes in Net Assets  
Morningstar International Moat ETF 18
Morningstar Wide Moat ETF 18
NDR CMG Long/Flat Allocation ETF 19
Spin-Off ETF 19
Financial Highlights  
Morningstar International Moat ETF 20
Morningstar Wide Moat ETF 20
NDR CMG Long/Flat Allocation ETF 21
Spin-Off ETF 21
Notes to Financial Statements 22
Approval of Investment Management Agreement 29

 

The information contained in the management discussion represents the opinions of VanEck Vectors ETF Trust and may differ from other persons. This information is not intended to be a forecast of future events, a guarantee of future results or investment advice. The information contained herein regarding each index has been provided by the relevant index provider. Also, unless otherwise specifically noted, any discussion of the Funds’ holdings and the Funds’ performance, and the views of VanEck Vectors ETF Trust are as of March 31, 2018, and are subject to change.

 

VANECK VECTORS ETFs

March 31, 2018 (unaudited)

 

Dear Shareholder:

 

We are pleased to present this semi-annual report for the six-month period ended March 31, 2018. Our three strategic equity exchange-traded funds (ETFs) of the VanEck Vectors® ETF Trust are now joined by the first of our guided allocation ETFs—VanEck Vectors NDR CMG Long/Flat Allocation ETF (NYSE Arca: LFEQ).

 

Managing Risk in the U.S. Equity Market

 

Building on our existing relationship with Ned Davis Research (NDR), the world-renowned provider of institutional quality research, we launched a new ETF with a guided allocation approach aimed at helping investors manage risk in the U.S. equity market.

 

Launched on October 4, 2017, LFEQ is designed to guide investors through volatile markets by opportunistically allocating between U.S. equity and cash. While many investors make an allocation to U.S. equity for the long-term growth potential, most probably do not realize that since 1928 the S&P 500® Index1 has spent approximately 70% of the time either in a bear market or recovering from one.2 This leaves the balance of time, only about 30%, available for the opportunity to generate new wealth.

 

Equity Markets Spent 70% of the Time in Market Decline and Recovery Periods 1/3/1928 - 3/31/2018

 

 

Source: Ned Davis Research, FactSet, S&P Dow Jones Indices. Based on price return, which excludes dividends. If calculated on a total return basis the figure would be 59%. Data as of 3/31/2018. Data plotted to logarithmic scale. For illustrative purposes only. Past performance is no guarantee of future results. See disclosures and index descriptions and definitions below.

 

For any investor, that is not a great deal of time spent growing new wealth. However, an investor’s experience will depend on where in the market cycle she or he starts investing. LFEQ provides investors with an ETF solution that offers a systematic approach that seeks both to participate in uptrends with a full allocation to equity and preserve capital by raising cash as market health weakens.

 

LFEQ seeks to track the Ned Davis Research CMG US Large Cap Long/Flat Index3 (NDRCMGLF). This is a rules-based index that follows a proprietary model developed by NDR and CMG Capital Management Group, Inc. The model produces trade signals that dictate the index’s equity allocation (100%, 80%, 40%, or 0%) and/or cash (U.S. T-bills) allocation.

1

VANECK VECTORS ETFs

(unaudited) (continued)

 

Second Partnership with Ned Davis Research

 

LFEQ is the second partnership between VanEck and Ned Davis Research, joining the VanEck® NDR Managed Allocation Fund (NDRMX), a tactical allocation mutual fund launched in May 2016. NDRMX follows a flexible NDR model allocating between U.S. and non-U.S. equity, U.S. debt, and U.S. cash and cash equivalents.

 

Access investment and market insights from VanEck’s investment professionals by subscribing to our blogs. To subscribe to the guided allocation updates, please contact us at 800.826.2333 or visit vaneck.com/subscription to register.

 

Thank you for participating in the VanEck Vectors ETF Trust. On the following pages, you will find the performance record of each of the funds for the six-month period ending March 31, 2018. You will also find their financial statements. We value your continuing confidence in us and look forward to helping you meet your investment goals in the future.

 

 

 

Jan F. van Eck
Trustee and President
VanEck Vectors ETF Trust

 

April 16, 2018

 

Represents the opinions of the investment adviser. Past performance is no guarantee of future results. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.

 

1 S&P 500® Index consists of 500 widely held common stocks covering the leading industries in the U.S. economy.
   
2 Source: Ned Davis Research, S&P Dow Jones Indices. Based on price return, which excludes dividends. If calculated on a total return basis the figure would be 59%. Data as of 3/31/2018. Past performance is not indicative of future correlation or results.
   
3 Ned Davis Research CMG US Large Cap Long/Flat Index (NDRCMGLF) is a rules-based index that follows a proprietary model developed by Ned Davis Research, Inc. (“NDR”) in conjunction with CMG Capital Management Group, Inc. (“CMG”). The model produces daily trade signals to determine the Index’s equity allocation percentage (100%, 80%, 40%, or 0%). When allocated to a percentage of equities (long), that portion of the Index will comprise the S&P 500® Index. When allocated to a percentage of cash (flat), that portion of the Index will be allocated to the Solactive13-week U.S. T-bill Index.

 

Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Certain indices may take into account withholding taxes. Investors cannot invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

 

VanEck Vectors NDR CMG Long/Flat Allocation ETF (the “Fund”) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Ned Davis Research CMG US Large Cap Long/Flat Index (the “Index”).

 

The Fund is not sponsored, endorsed, sold or promoted by Ned Davis Research, Inc. or CMG Capital Management Group, Inc. NDR and CMG make no representation or warranty, express or implied, to the owners of the Fund or any member of the public regarding the advisability of investing in securities generally or in the Fund particularly or the ability of the Index to track the performance of equities market.

 

NEITHER NDR NOR CMG GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE INDEX OR ANY DATA INCLUDED THEREIN AND NEITHER NDR NOR CMG SHALL HAVE ANY LIABILITY WHATSOEVER FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. NDR AND CMG MAKE NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY LICENSEE, OWNERS OF THE FUND, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE INDEX OR ANY DATA INCLUDED THEREIN. NDR AND CMG MAKE NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL NDR OR CMG HAVE ANY LIABILITY, JOINTLY OR SEVERALLY, FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

2

 

 

The S&P 500 Index is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Van Eck Associates Corporation. Copyright © 2018 S&P Dow Jones Indices LLC, a division of S&P Global, Inc., and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC. For more information on any of S&P Dow Jones Indices LLC’s indices please visit www.spdji.com. S&P® is a registered trademark of S&P Global and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC. Neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors make any representation or warranty, express or implied, as to the ability of any index to accurately represent the asset class or market sector that it purports to represent and neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors shall have any liability for any errors, omissions, or interruptions of any index or the data included therein.

3

VANECK VECTORS ETFs

(unaudited)

 

Management Discussion (unaudited)

 

All three VanEck Vectors Strategic Equity ETFs that traded for the full six-month period posted positive returns. Since VanEck Vectors NDR CMG Long/Flat Allocation ETF (LFEQ) was launched on October 4, 2017, it did not trade for the full reporting period.

 

 

Source: VanEck. Returns based on NAV. The performance data quoted represent past performance. Past performance is not a guarantee of future results. Performance information for the Funds reflects temporary waivers of expenses and/or fees. Had the Funds incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Funds will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than performance data quoted.

 

Morningstar International Moat

 

For the six-month period, VanEck Vectors Morningstar International Moat ETF (NYSE Arca: MOTI) returned 1.87%.* The primary drivers of the Fund’s performance were the financials and consumer discretionary sectors. The healthcare sector detracted most from performance followed by the energy and materials sectors.

 

Morningstar Wide Moat

 

VanEck Vectors Morningstar Wide Moat ETF (NYSE Arca: MOAT) returned 3.83%* for the six-month period. The primary driver of performance was the Fund’s exposure to the consumer discretionary sector. In addition, stocks in the information technology and financials sectors contributed solid positive returns. The health care sector was the single largest detractor from the Fund’s performance.

 

NDR CMG Long/Flat Allocation

 

Since inception on October 4, 2017, the Fund had traded for under six months by March 31, 2018. The Fund was up 4.11%.* The Fund’s allocation to equities changed twice during the period. In light of deteriorating market health, the Fund’s exposure to equites was reduced from 100% to 80% on November 22, 2017. However, on December 27, 2017, reacting quickly to increasing market health, the Fund’s allocation to equities returned to 100%, at which level it remained through the end of the period under review.

 

Spin-Off

 

VanEck Vectors Spin-Off ETF (NYSE Arca: SPUN) returned 2.79%.* During the six-month period, U.S. companies were by far the largest contributors to the Fund’s total returns. Ireland and the Cayman Islands were the largest detractors from performance. The three sectors contributing the most to performance were information technology, consumer discretionary, and materials. The energy, real estate, and utilities sectors were the only negative contributors to the Fund’s performance.

 

* Returns based on NAV.
4

VANECK VECTORS ETF TRUST

EXPLANATION OF EXPENSES

(unaudited)

 

Hypothetical $1,000 investment at beginning of period

As a shareholder of a Fund, you incur operating expenses, including management fees and other Fund expenses. This disclosure is intended to help you understand the ongoing costs (in dollars) of investing in your Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

 

The disclosure is based on an investment of $1,000 invested at the beginning of the period and held for the entire period, October 1, 2017 to March 31, 2018.

 

Actual Expenses

The first line in the table below provides information about account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period.”

 

Hypothetical Example for Comparison Purposes

The second line in the table below provides information about hypothetical account values and hypothetical expenses based on the Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

 

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

 

   Beginning
Account
Value
October 1, 2017
  Ending
Account
Value
March 31, 2018
  Annualized
Expense
Ratio
During Period
  Expenses Paid
During the Period*
October 1, 2017 –
March 31, 2018
Morningstar International Moat ETF                    
Actual  $1,000.00   $1,018.70    0.57%         $2.87    
Hypothetical**  $1,000.00   $1,022.09    0.57%  $2.87 
Morningstar Wide Moat ETF                    
Actual  $1,000.00   $1,038.30    0.48%  $2.44 
Hypothetical**  $1,000.00   $1,022.54    0.48%  $2.42 
NDR CMG Long/Flat Allocation ETF***                    
Actual  $1,000.00   $1,041.10    0.55%  $2.74 
Hypothetical**  $1,000.00   $1,022.19    0.55%  $2.77 
Spin-Off ETF                    
Actual  $1,000.00   $1,027.90    0.55%  $2.78 
Hypothetical**  $1,000.00   $1,022.19    0.55%  $2.77 

 

* Expenses are equal to the Fund’s annualized expense ratio (for the six months ended March 31, 2018) multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year divided by the number of days in the fiscal year (to reflect the one-half year period).
   
** Assumes annual return of 5% before expenses
   
*** Expenses are equal to the Fund’s annualized expense ratio (for the period from October 4, 2017 (commencement of operations) to March 31, 2018), multiplied by the average account value over the period, multiplied by the number of days since commencement of operations divided by the number of days in the fiscal year.
5

VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value
         
COMMON STOCKS: 98.1%
Australia: 4.0%
 144,899   Brambles Ltd. #  $1,116,855 
 16,831   Commonwealth Bank of Australia #   939,995 
 114,328   Crown Ltd. #   1,121,361 
 39,866   Westpac Banking Corp. #   881,860 
         4,060,071 
Belgium: 1.0%
 11,925   KBC Group NV #   1,037,910 
Canada: 3.8%
 11,375   Canadian Imperial Bank of Commerce   1,003,347 
 20,858   National Bank of Canada   981,058 
 21,027   Nutrien Ltd.   993,084 
 21,641   TransCanada Corp.   894,344 
         3,871,833 
China / Hong Kong: 16.3%
 3,917,000   Bank of China Ltd. #   2,139,657 
 740,000   Beijing Capital International Airport Co. Ltd. #   999,409 
 368,500   Beijing Enterprises Holdings Ltd. #   1,940,516 
 600,000   China Resources Gas Group Ltd. #   2,098,158 
 247,000   CK Asset Holdings Ltd. #   2,084,411 
 155,200   Hongkong Land Holdings Ltd. (USD) #   1,072,279 
 2,442,000   Industrial & Commercial Bank of China Ltd. #   2,128,128 
 9,388   SINA Corp. (USD) *   978,887 
 127,000   Sun Hung Kai Properties Ltd. #   2,015,829 
 22,600   Tencent Holdings Ltd. #   1,213,135 
         16,670,409 
Denmark: 1.0%
 26,282   Danske Bank A/S #   984,368 
France: 2.8%
 120,737   Orange SA #   2,051,269 
 10,487   Sanofi #   841,068 
         2,892,337 
Germany: 11.8%
 16,297   Bayer AG #   1,836,327 
 19,714   Bayerische Motoren Werke AG #   2,143,242 
 42,649   GEA Group AG #   1,812,840 
 10,340   HeidelbergCement AG #   1,015,327 
 24,461   KION Group AG #   2,282,583 
 15,085   Siemens AG #   1,923,868 
 12,941   Symrise AG #   1,041,495 
         12,055,682 
India: 2.1%    
 68,780   Infosys Ltd. #   1,203,527 
 221,551   Wipro Ltd. #   959,736 
         2,163,263 
Italy: 2.0%       
 2,208,558   Telecom Italia SpA * #   2,095,991 
Japan: 12.1%
 11,400   East Japan Railway Co. #   1,066,381 
 4,300   FANUC Corp. #   1,107,191 
 11,700   Hoshizaki Corp. #   1,043,607 
 14,000   Kao Corp. #   1,051,573 
 37,200   KDDI Corp. #   958,560 
Number       
of Shares      Value
         
Japan: (continued)
 60,700   Kubota Corp. #  $1,070,549 
 26,800   LINE Corp. * #   1,055,268 
 6,700   Nidec Corp. #   1,031,722 
 25,600   Seven & i Holdings Co. Ltd. #   1,097,075 
 24,200   SoftBank Group Corp. #   1,806,042 
 37,300   Unicharm Corp. #   1,076,421 
         12,364,389 
Luxembourg: 2.1%
 31,816   Millicom International Cellular SA (SEK) #   2,170,818 
Mexico: 5.0%
 1,165,200   America Movil, SAB de CV   1,101,142 
 408,500   Grupo Aeroportuario del Centro Norte SAB de CV   1,983,922 
 211,700   Grupo Aeroportuario del Pacifico SAB de CV   2,083,309 
         5,168,373 
Netherlands: 2.9%
 336,693   Koninklijke KPN NV #   1,011,940 
 51,623   Koninklijke Philips NV #   1,975,786 
         2,987,726 
New Zealand: 1.0%
 256,666   Contact Energy Ltd. #   977,009 
Russia: 1.0%
 206,048   Mobile TeleSystems PJSC #   1,055,437 
Singapore: 4.1%
 751,800   CapitaLand Ltd. #   2,058,562 
 1,230,200   Genting Singapore Plc #   1,020,240 
 115,701   Oversea-Chinese Banking Corp. Ltd. #   1,139,640 
         4,218,442 
South Korea: 1.0%
 4,829   SK Telecom Co. Ltd. #   1,047,104 
Spain: 5.1%
 127,415   Banco Bilbao Vizcaya Argentaria SA #   1,008,581 
 92,429   Gas Natural SDG SA #   2,205,027 
 36,729   Grifols SA #   1,040,791 
 97,302   Telefonica SA #   963,487 
         5,217,886 
Sweden: 3.6%
 171,995   Nordea Bank AB #   1,834,847 
 75,306   Svenska Handelsbanken AB #   939,779 
 39,800   Swedbank AB #   891,650 
         3,666,276 
Switzerland: 2.0%
 18,818   LafargeHolcim Ltd. #   1,029,403 
 4,338   Roche Holding AG #   993,462 
         2,022,865 
United Kingdom: 11.3%
 237,360   GKN Plc #   1,538,314 
 2,223,901   Lloyds Banking Group Plc #   2,022,631 
 308,752   Meggitt Plc #   1,872,786 
 81,607   Rolls-Royce Holdings Plc #   997,595 
 95,920   Smiths Group Plc #   2,040,057 


 

See Notes to Financial Statements

6

 

 

Number       
of Shares      Value
         
United Kingdom: (continued)
 19,904   Unilever Plc #  $1,103,769 
 717,684   Vodafone Group Plc #   1,963,326 
         11,538,478 
United States: 2.1%
 478,200   Samsonite International SA (HKD) #   2,187,156 
Total Common Stocks
(Cost: $97,504,905)
   100,453,823 
Number        
of Shares       Value
            
REAL ESTATE INVESTMENT TRUSTS: 2.1%
(Cost: $2,101,101)
Singapore: 2.1%
  1,373,200    CapitaLand Mall Trust #  $2,185,637 
Total Investments: 100.2%
(Cost: $99,606,006)
   102,639,460 
Liabilities in excess of other assets: (0.2)%  (217,704)
NET ASSETS: 100.0%  $102,421,756 


 

 

Definitions:

HKD Hong Kong Dollar
SEK Swedish Krona
USD United States Dollar

Footnotes:

* Non-income producing
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $92,620,367 which represents 90.4% of net assets.

 

Summary of Investments by Sector  % of Investments  Value  
Consumer Discretionary   7.8%  $8,010,313 
Consumer Staples   4.2    4,328,838 
Energy   0.9    894,344 
Financials   17.5    17,933,451 
Health Care   6.5    6,687,434 
Industrials   23.7    24,373,190 
Information Technology   5.3    5,410,553 
Materials   4.0    4,079,309 
Real Estate   9.2    9,416,718 
Telecommunication Services   15.8    16,225,116 
Utilities   5.1    5,280,194 
            100.0%  $102,639,460 

 

See Notes to Financial Statements

7

VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks                      
Australia  $   $4,060,071     $   $4,060,071 
Belgium       1,037,910          1,037,910 
Canada   3,871,833              3,871,833 
China / Hong Kong   978,887    15,691,522          16,670,409 
Denmark       984,368          984,368 
France       2,892,337          2,892,337 
Germany       12,055,682          12,055,682 
India       2,163,263          2,163,263 
Italy       2,095,991          2,095,991 
Japan       12,364,389          12,364,389 
Luxembourg       2,170,818          2,170,818 
Mexico   5,168,373              5,168,373 
Netherlands       2,987,726          2,987,726 
New Zealand       977,009          977,009 
Russia       1,055,437          1,055,437 
Singapore       4,218,442          4,218,442 
South Korea       1,047,104          1,047,104 
Spain       5,217,886          5,217,886 
Sweden       3,666,276          3,666,276 
Switzerland       2,022,865          2,022,865 
United Kingdom       11,538,478          11,538,478 
United States       2,187,156          2,187,156 
Real Estate Investment Trusts*       2,185,637          2,185,637 
Total  $10,019,093   $92,620,367     $   $102,639,460 

 

* See Schedule of Investments for geographic sector breakouts.

 

During the period ended March 31, 2018, transfers of securities from Level 2 to Level 1 were $3,019,905. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.

 

See Notes to Financial Statements

8

VANECK VECTORS MORNINGSTAR WIDE MOAT ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number       
of Shares      Value
         
COMMON STOCKS: 99.7%
Banks: 2.4%
 614,289   Wells Fargo & Co.  $32,194,886 
Capital Goods: 6.0%
 261,493   Emerson Electric Co.   17,859,972 
 2,063,085   General Electric Co.   27,810,386 
 59,371   TransDigm Group, Inc. †   18,223,335 
 139,711   United Technologies Corp.   17,578,438 
         81,472,131 
Commercial & Professional Services: 2.2%
 512,501   Stericycle, Inc. *   29,996,684 
Consumer Durables & Apparel: 2.8%
 307,744   NIKE, Inc.   20,446,511 
 238,757   VF Corp.   17,696,669 
         38,143,180 
Consumer Services: 3.9%
 117,126   McDonald’s Corp.   18,316,164 
 616,477   Starbucks Corp.   35,687,854 
         54,004,018 
Diversified Financials: 3.6%
 175,044   American Express Co.   16,328,104 
 321,986   Charles Schwab Corp.   16,814,109 
 454,025   Franklin Resources, Inc.   15,745,587 
         48,887,800 
Energy: 1.3%
 330,207   Cheniere Energy, Inc. *   17,649,564 
Food & Staples Retailing: 2.3%
 507,765   CVS Caremark Corp.   31,588,061 
Food, Beverage & Tobacco: 7.6%
 414,293   Campbell Soup Co. †   17,943,030 
 349,544   General Mills, Inc.   15,750,453 
 178,692   Hershey Co.   17,683,360 
 829,655   Mondelez International, Inc.   34,621,503 
 162,489   PepsiCo, Inc.   17,735,674 
         103,734,020 
Health Care Equipment & Services: 16.1%
 400,968   AmerisourceBergen Corp.   34,567,451 
 523,268   Cardinal Health, Inc.   32,798,438 
 518,963   Express Scripts Holding Co. *   35,849,964 
 237,874   McKesson Corp.   33,509,310 
 424,878   Medtronic Plc   34,083,713 
 269,144   Veeva Systems, Inc. *   19,652,895 
 281,073   Zimmer Biomet Holdings, Inc.   30,648,200 
         221,109,971 
Household & Personal Products: 1.3%
 225,464   The Procter and Gamble Co.   17,874,786 
Materials: 4.8%
 539,963   Compass Minerals International, Inc. †   32,559,769 
 283,082   Monsanto Co.   33,032,839 
         65,592,608 
Number       
of Shares      Value
         
Media: 8.2%
 494,124   Comcast Corp.  $16,884,217 
 305,512   John Wiley & Sons, Inc.   19,461,114 
 1,127,584   Twenty-First Century Fox, Inc.   41,371,057 
 344,689   Walt Disney Co.   34,620,563 
         112,336,951 
Pharmaceuticals, Biotechnology: 17.2%
 208,866   Allergan Plc   35,150,059 
 191,598   Amgen, Inc.   32,663,627 
 116,404   Biogen Idec, Inc. *   31,873,743 
 267,381   Bristol-Myers Squibb Co.   16,911,848 
 432,956   Eli Lilly & Co.   33,497,806 
 220,196   Gilead Sciences, Inc.   16,600,576 
 628,866   Merck and Co., Inc.   34,254,331 
 970,841   Pfizer, Inc.   34,455,147 
         235,407,137 
Retailing: 7.7%
 26,539   Amazon.com, Inc. *   38,410,956 
 802,674   L Brands, Inc.   30,670,174 
 417,904   Lowe’s Cos, Inc.   36,671,076 
         105,752,206 
Semiconductor: 2.4%     
 364,170   Microchip Technology, Inc.   33,270,571 
Software & Services: 8.7%     
 194,559   Guidewire Software, Inc. *   15,726,204 
 190,151   Microsoft Corp.   17,355,082 
 303,950   Salesforce.com, Inc. *   35,349,385 
 1,729,786   The Western Union Co.   33,263,785 
 150,367   Visa, Inc.   17,986,901 
         119,681,357 
Utilities: 1.2%
 244,857   Dominion Resources, Inc.   16,510,708 
Total Common Stocks
(Cost: $1,346,915,369)
   1,365,206,639 
          
Principal
Amount
         
SHORT-TERM INVESTMENTS HELD AS     
COLLATERAL FOR SECURITIES ON LOAN: 2.3%     
Repurchase Agreements: 2.3%     
$7,558,818   Repurchase agreement dated  3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18,  proceeds $7,560,347;  (collateralized by various U.S. government and agency  obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67,  valued at $7,709,994 including accrued interest)   7,558,818 
 1,589,409   Repurchase agreement dated  3/29/18 with Credit Agricole CIB, 1.75%, due 4/2/18, proceeds $1,589,718; (collateralized by various U.S. government and agency obligations, 1.50% to 1.63%, due 12/31/18 to 10/15/20, valued at $1,621,197 including accrued interest)   1,589,409 


 

See Notes to Financial Statements

9

VANECK VECTORS MORNINGSTAR WIDE MOAT ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

Principal       
Amount      Value
         
Repurchase Agreements: (continued)
$7,558,818   Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $7,560,338; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $7,709,995 including accrued interest)   $7,558,818 
 7,558,818   Repurchase agreement dated 3/29/18 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.81%, due 4/2/18, proceeds $7,560,338; (collateralized by various U.S. government and agency obligations, 0.00% to 4.50%, due 12/1/26 to 4/1/48, valued at $7,709,994 including accrued interest)   7,558,818 
Principal        
Amount       Value
          
Repurchase Agreements: (continued)
$ 7,558,818    Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $7,560,347; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $7,709,994 including accrued interest)  $7,558,818 
Total Short-Term Investments Held as Collateral for Securities on Loan
(Cost: $31,824,681)
 31,824,681 
Total Investments: 102.0%
(Cost: $1,378,740,050)
 1,397,031,320 
Liabilities in excess of other assets: (2.0)%   (27,903,130)
NET ASSETS: 100.0%  $1,369,128,190 


 

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $31,807,762.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments  Value 
Consumer Discretionary   22.7%  $310,236,355 
Consumer Staples   11.2    153,196,867 
Energy   1.3    17,649,564 
Financials   5.9    81,082,686 
Health Care   33.5    456,517,108 
Industrials   8.2    111,468,815 
Information Technology   11.2    152,951,928 
Materials   4.8    65,592,608 
Utilities   1.2    16,510,708 
            100.0%  $1,365,206,639 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $1,365,206,639   $     $   $1,365,206,639 
Repurchase Agreements       31,824,681          31,824,681 
Total  $1,365,206,639   $31,824,681     $   $1,397,031,320 

 

* See Schedule of Investments for industry sector breakouts.

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

10

VANECK VECTORS NDR CMG LONG/FLAT ALLOCATION ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number        
of Shares       Value
 
EXCHANGE TRADED FUND: 99.6%
(Cost: $35,705,043)
  144,280    Vanguard S&P 500 ETF  $34,927,302 
MONEY MARKET FUND: 0.5%
(Cost: $160,096)
  160,096    Dreyfus Government Cash Management Fund – Institutional Shares   160,096 
Total Investments: 100.1%
(Cost: $35,865,139)
 35,087,398 
Liabilities in excess of other assets: (0.1)%   (35,188)
NET ASSETS: 100.0%  $35,052,210 

 

Summary of Investments by Sector  % of Investments  Value 
Exchange Traded Fund   99.5%  $34,927,302 
Money Market Fund   0.5    160,096 
             100.0%  $35,087,398 

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Exchange Traded Fund  $34,927,302   $     $   $34,927,302 
Money Market Fund   160,096              160,096 
Total  $35,087,398   $     $   $35,087,398 

 

There were no transfers between levels during the period ended March 31, 2018.

 

See Notes to Financial Statements

11

VANECK VECTORS SPIN-OFF ETF

SCHEDULE OF INVESTMENTS

March 31, 2018 (unaudited)

 

Number
of Shares
      Value 
      
COMMON STOCKS: 85.8%     
Australia: 2.2%     
 20,395   Orora Ltd. #  $52,038 
 20,033   South32 Ltd. #   50,281 
         102,319 
Cayman Islands: 1.0%     
 1,887   Theravance Biopharma, Inc. (USD) * †   45,760 
China / Hong Kong: 4.1%     
 145,000   China Overseas Property Holdings Ltd. #   45,814 
 6,000   CK Asset Holdings Ltd. #   50,633 
 854,000   Global Brands Group Holding Ltd. * #   48,319 
 8,000   Wharf Real Estate Investment Co. Ltd. * #   52,290 
         197,056 
Denmark: 1.1%     
 1,083   Nilfisk Holding A/S * #   51,075 
Finland: 2.1%     
 6,688   Caverion Corp. * † #   50,616 
 2,574   Valmet OYJ #   51,578 
         102,194 
France: 1.1%     
 504   Fnac Darty SA * #   53,911 
Germany: 2.1%     
 2,776   METRO AG #   49,084 
 685   OSRAM Licht AG #   50,383 
         99,467 
Ireland: 1.1%     
 617   Allegion Plc (USD)   52,624 
Italy: 1.1%     
 8,976   Italgas SpA #   53,609 
Norway: 1.1%     
 9,427   Aker Solutions ASA * # Reg S   50,245 
Singapore: 1.1%     
 34,900   Frasers Centrepoint Ltd. #   53,319 
Sweden: 3.3%     
 17,464   Arjo AB * #   50,890 
 3,878   Bonava AB #   53,110 
 5,097   Svenska Cellulosa AB #   54,307 
         158,307 
Switzerland: 1.1%     
 2,116   Idorsia Ltd. * #   50,819 
United Kingdom: 3.4%     
 1,096   Delphi Technologies PLC (USD)   52,224 
 32,904   Gocompare.Com Group Plc   51,697 
 9,058   Indivior Plc * #   51,771 
 478   Micro Focus International Plc (ADR)   6,711 
         162,403 
United States: 59.9%     
 871   Adient Plc   52,051 
 1,480   AdvanSix, Inc. *   51,474 
 1,162   Alcoa Corp. *   52,244 
 1,434   Associated Capital Group, Inc. †   53,703 
 996   Brighthouse Financial, Inc. *   51,194 
 76   Cable One, Inc.   52,220 
 3,262   California Resources Corp. * †   55,943 
 1,750   Cars.com, Inc. *   49,578 
Number
of Shares
      Value 
           
United States: (continued)     
 800   CDK Global, Inc.  $50,672 
 1,073   Chemours Co.   52,266 
 13,278   Civeo Corp. *   50,058 
 2,694   Conduent, Inc. * †   50,216 
 1,774   CONSOL Energy, Inc. *   51,393 
 1,139   CSW Industrials, Inc. *   51,312 
 2,994   Donnelley Financial Solutions, Inc. *   51,407 
 1,002   Energizer Holdings, Inc. †   59,699 
 2,361   Enova International, Inc. *   52,060 
 1,881   Exterran Corp. *   50,223 
 680   Fortive Corp.   52,714 
 5,218   Gannett Co., Inc. †   52,076 
 1,775   GCP Applied Technologies, Inc. *   51,564 
 1,110   Halyard Health, Inc. *   51,149 
 770   Herc Holdings, Inc. * †   50,012 
 2,848   Hewlett Packard Enterprise Co.   49,954 
 1,198   Hilton Grand Vacations, Inc. *   51,538 
 695   Ingevity Corp. *   51,215 
 2,912   International Seaways, Inc. *   51,251 
 1,006   Keysight Technologies, Inc. *   52,704 
 751   KLX, Inc. *   53,366 
 4,027   Knowles Corp. * †   50,700 
 956   Lamb Weston Holdings, Inc.   55,658 
 2,456   Lands’ End, Inc. *   57,348 
 612   Liberty Broadband Corp. *   51,898 
 2,870   LSC Communications, Inc.   50,081 
 756   Lumentum Holdings, Inc. * †   48,233 
 214   Madison Square Garden Co. *   52,601 
 3,647   Mallinckrodt Plc * †   52,809 
 742   Murphy USA, Inc. * †   54,018 
 3,977   Navient Corp.   52,178 
 2,987   New Media Investment Group, Inc. †   51,197 
 3,207   News Corp.   50,671 
 4,801   NOW, Inc. * †   49,066 
 799   ONE Gas, Inc.   52,750 
 664   PayPal Holdings, Inc. *   50,378 
 1,727   Pinnacle Entertainment, Inc. * †   52,069 
 1,065   PJT Partners, Inc. †   53,356 
 2,616   Rayonier Advanced Materials, Inc. †   56,166 
 689   Science Applications International Corp.   54,293 
 1,007   SPX FLOW, Inc. *   49,534 
 3,294   TimkenSteel Corp. * †   50,036 
 658   TopBuild Corp. *   50,350 
 1,440   Varex Imaging Corp. *   51,523 
 1,368   Versum Materials, Inc.   51,478 
 3,182   Vista Outdoor, Inc. *   51,930 
 2,653   Welbilt, Inc. *   51,601 
         2,857,178 
     
Total Common Stocks
(Cost: $3,545,438)
   4,090,286 
REAL ESTATE INVESTMENT TRUSTS: 14.4%     
United States: 14.4%     
 3,781   CareTrust REIT, Inc.   50,665 
 9,236   Colony NorthStar, Inc. †   51,906 
 2,329   Four Corners Property Trust, Inc.   53,777 
 1,575   Gaming and Leisure Properties, Inc.   52,715 
 3,114   New Residential Investment Corp.   51,225 
 6,639   New Senior Investment Group, Inc.   54,307 


 

See Notes to Financial Statements

12

 

 

Number
of Shares
      Value 
           
United States: (continued)     
 4,125   NorthStar Realty Europe Corp.  $53,707 
 1,979   Park Hotels and Resorts, Inc.   53,473 
 2,724   Quality Care Properties, Inc. *   52,927 
 3,192   Uniti Group, Inc. * †   51,870 
 2,517   Urban Edge Properties   53,738 
 8,091   Washington Prime Group, Inc. †   53,967 
 2,654   Xenia Hotels and Resorts, Inc.   52,337 
Total Real Estate Investment Trusts
(Cost: $751,465)
   686,614 
MONEY MARKET FUND: 0.4%
(Cost: $21,887)
     
 21,887   Dreyfus Government Cash Management Fund – Institutional Shares   21,887 
Total Investments Before Collateral for Securities Loaned: 100.6%
(Cost: $4,318,790)
   4,798,787 
Principal
Amount
      Value 
           
SHORT-TERM INVESTMENT HELD AS     
COLLATERAL FOR SECURITIES ON LOAN: 19.1%
(Cost: $909,458)
     
Repurchase Agreement: 19.1%     
$909,458   Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $909,642; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $927,647 including accrued interest)  $909,458 
Total Investments: 119.7%
(Cost: $5,228,248)
   5,708,245 
Liabilities in excess of other assets: (19.7)%   (938,984)
NET ASSETS: 100.0%  $4,769,261 


 

 

Definitions:

ADR American Depositary Receipt
USD United States Dollar

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $904,903.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $1,024,092 which represents 21.5% of net assets.
Reg S Security was purchased pursuant to Regulation S under the Securities Act of 1933, which exempts from registration securities offered and sold outside of the United States. Such a security cannot be sold in the United States without either an effective registration statement filed pursuant to the Securities Act of 1933, or pursuant to an exemption from registration.

 

Summary of Investments by Sector
Excluding Collateral for Securities Loaned
  % of Investments  Value 
Consumer Discretionary   18.5%  $887,531 
Consumer Staples   3.4    164,441 
Energy   5.4    259,055 
Financials   7.6    365,123 
Health Care   7.4    354,721 
Industrials   15.9    763,598 
Information Technology   10.8    517,036 
Materials   10.9    521,591 
Real Estate   17.4    837,445 
Utilities   2.2    106,359 
Money Market Fund   0.5    21,887 
          100.0%        $4,798,787 

 

See Notes to Financial Statements

13

VANECK VECTORS SPIN-OFF ETF

SCHEDULE OF INVESTMENTS

(unaudited) (continued)

 

The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks                      
Australia  $   $102,319     $   $102,319 
Cayman Islands   45,760              45,760 
China / Hong Kong       197,056          197,056 
Denmark       51,075          51,075 
Finland       102,194          102,194 
France       53,911          53,911 
Germany       99,467          99,467 
Ireland   52,624              52,624 
Italy       53,609          53,609 
Norway       50,245          50,245 
Singapore       53,319          53,319 
Sweden       158,307          158,307 
Switzerland       50,819          50,819 
United Kingdom   110,632    51,771          162,403 
United States   2,857,178              2,857,178 
Real Estate Investment Trusts*   686,614              686,614 
Money Market Fund   21,887              21,887 
Repurchase Agreement       909,458          909,458 
Total  $3,774,695   $1,933,550     $   $5,708,245 

 

* See Schedule of Investments for geographic sector breakouts.

 

During the period ended March 31, 2018, transfers of securities from Level 1 to Level 2 were $329,139, transfers of securities from Level 2 to Level 1 were $56,353. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.

 

See Notes to Financial Statements

14

[This Page Intentionally Left Blank.]

15

VANECK VECTORS ETF TRUST

STATEMENTS OF ASSETS AND LIABILITIES

March 31, 2018 (unaudited)

 

        Morningstar
International
Moat ETF
   Morningstar
Wide Moat ETF
   NDR CMG
Long/Flat
Allocation ETF
   Spin-Off ETF  
                          
Assets:                      
Investments, at value (1) (2)    $102,639,460   $1,365,206,639   $35,087,398   $4,798,787 
Short-term investments held as collateral for securities loaned (3)         31,824,681        909,458 
Cash         1,189,309        124 
Cash denominated in foreign currency, at value (4)     197,712             
Receivables:                      
   Investment securities sold     179,277            641,252 
   Shares sold         1,360    394     
   Due from Adviser                 6,539 
   Dividends and interest     293,714    3,347,371    60    14,304 
Prepaid expenses     393    9,761        45 
   Total assets     103,310,556    1,401,579,121    35,087,852    6,370,509 
                          
Liabilities:                      
Payables:                      
   Investment securities purchased     177,940            656,324 
   Collateral for securities loaned         31,824,681        909,458 
   Line of credit     635,888             
   Shares redeemed         453         
   Due to Adviser     36,153    546,058    6,501     
   Due to custodian     3,306             
Deferred Trustee fees     221    34,984    2    30 
Accrued expenses     35,292    44,755    29,139    35,436 
   Total liabilities     888,800    32,450,931    35,642    1,601,248 
NET ASSETS    $102,421,756   $1,369,128,190   $35,052,210   $4,769,261 
Shares outstanding     3,000,000    33,050,000    1,350,000    200,000 
Net asset value, redemption and offering price per share    $34.14   $41.43   $25.96   $23.85 
                          
Net assets consist of:                      
   Aggregate paid in capital    $96,047,076   $1,395,527,036   $35,599,216   $3,827,475 
   Net unrealized appreciation (depreciation)     3,035,154    18,291,269    (777,741)   479,996 
   Undistributed (accumulated) net investment income (loss)     (107,753)   8,951,607    90,244    14,819 
   Accumulated net realized gain (loss)     3,447,279    (53,641,722)   140,491    446,971 
        $102,421,756   $1,369,128,190   $35,052,210   $4,769,261 
(1)  Value of securities on loan    $   $31,807,762   $   $904,903 
(2)  Cost of investments    $99,606,006   $1,346,915,369   $35,865,139   $4,318,790 
(3)  Cost of short-term investments held as collateral for securities loaned    $   $31,824,681   $   $909,458 
(4)  Cost of cash denominated in foreign currency    $198,149   $   $   $ 

 

See Notes to Financial Statements

16

VANECK VECTORS ETF TRUST

STATEMENTS OF OPERATIONS

For the Six Months Ended March 31, 2018 (unaudited)

 

   Morningstar
International
Moat ETF
    Morningstar
Wide Moat ETF
    NDR CMG
Long/Flat
Allocation
ETF (a)
    Spin-Off ETF  
                        
Income:                       
Dividends  $1,097,221    $13,999,117    $142,114    $44,865 
Interest             920      
Securities lending income   19,889     107,106          1,339 
Foreign taxes withheld   (123,694)              (1,098)
Total income   993,416     14,106,223     143,034     45,106 
                        
Expenses:                       
Management fees   217,280     3,036,720     29,809     13,383 
Professional fees   29,914     50,801     22,704     30,303 
Insurance   304     6,213          29 
Trustees’ fees and expenses   628     14,742     23     61 
Reports to shareholders   17,465     36,354     7,228     7,082 
Indicative optimized portfolio value fee   2,528     2,432     2,158     2,514 
Custodian fees   12,846     15,388     4,335     5,528 
Registration fees   2,518     9,201     2,479     2,552 
Transfer agent fees   1,210     1,101     1,188     1,212 
Fund accounting fees   4,474     23,782     1,282     650 
Interest   3,115     20,543           
Other   2,946     16,050     1,331     3,037 
Total expenses   295,228     3,233,327     72,537     66,351 
Waiver of management fees   (48,760)         (29,809)    (13,383)
Expenses assumed by the Adviser             (9,938)    (38,247)
Net expenses   246,468     3,233,327     32,790     14,721 
Net investment income   746,948     10,872,896     110,244     30,385 
                        
Net realized gain (loss) on:                       
Investments   1,962,729     10,702,440     8,365     189,409 
In-kind redemptions   1,519,103     70,449,341     132,126     322,707 
Foreign currency transactions and foreign denominated assets and liabilities   (8,268)              (122)
Net realized gain   3,473,564     81,151,781     140,491     511,994 
                        
Net change in unrealized appreciation (depreciation) on:                       
Investments   (3,371,615)    (49,482,221)    (777,741)    (369,354)
Foreign currency transactions and foreign denominated assets and liabilities   898               (24)
Net change in unrealized appreciation (depreciation)   (3,370,717)    (49,482,221)    (777,741)    (369,378)
Net Increase (Decrease) in Net Assets Resulting from Operations  $849,795    $42,542,456    $(527,006)   $173,001 

 

 
(a) For the period October 4, 2017 (commencement of operations) through March 31, 2018.

 

See Notes to Financial Statements

17

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   Morningstar
International Moat ETF
  Morningstar Wide Moat ETF
             
   For the Six
Months Ended
March 31,
2018
   For the Year
Ended
September 30,
2017
   For the Six
Months Ended
March 31,
2018
   For the Year
Ended
September 30,
2017
 
   (unaudited)       (unaudited)         
                     
Operations:                    
Net investment income  $746,948   $1,232,784   $10,872,896   $14,690,691 
Net realized gain   3,473,564    3,732,310    81,151,781    123,090,627 
Net change in unrealized appreciation (depreciation)   (3,370,717)   5,937,074    (49,482,221)   40,676,068 
Net increase in net assets resulting from operations   849,795    10,902,168    42,542,456    178,457,386 
                     
Dividends and Distributions to shareholders:                    
Dividends from net investment income   (2,100,550)   (407,000)   (14,227,200)   (9,710,400)
Distributions from net realized capital gains   (2,201,600)            
Total Dividends and Distributions   (4,302,150)   (407,000)   (14,227,200)   (9,710,400)
                     
Share transactions:**                    
Proceeds from sale of shares   34,846,745    58,380,932    341,806,753    698,870,832 
Cost of shares redeemed   (10,603,645)       (287,444,739)   (334,524,711)
Increase in net assets resulting from share transactions   24,243,100    58,380,932    54,362,014    364,346,121 
Total increase in net assets   20,790,745    68,876,100    82,677,270    533,093,107 
Net Assets, beginning of period   81,631,011    12,754,911    1,286,450,920    753,357,813 
Net Assets, end of period†  $102,421,756   $81,631,011   $1,369,128,190   $1,286,450,920 
† Including undistributed (accumulated) net investment income (loss)  $(107,753)  $1,245,849   $8,951,607   $12,305,911 
                     
** Shares of Common Stock Issued (no par value)                    
Shares sold   1,000,000    1,850,000    7,850,000    18,300,000 
Shares redeemed   (300,000)       (6,700,000)   (8,550,000)
Net increase   700,000    1,850,000    1,150,000    9,750,000 

 

See Notes to Financial Statements

18

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   NDR CMG Long/Flat
Allocation ETF
   Spin-Off ETF 
   For the Period
October 4, 2017*
through
March 31,
2018
   For the Six
Months Ended
March 31,
2018
   For the Year
Ended
September 30,
2017
 
   (unaudited)   (unaudited)     
                
Operations:               
Net investment income  $110,244   $30,385   $44,880 
Net realized gain (loss)   140,491    511,994    (35,954)
Net change in unrealized appreciation (depreciation)   (777,741)   (369,378)   572,438 
Net increase (decrease) in net assets resulting from operations   (527,006)   173,001    581,364 
                
Dividends and Distributions to shareholders:               
Dividends from net investment income   (20,000)   (56,000)   (48,600)
                
Share transactions:**               
Proceeds from sale of shares   38,224,281        2,202,041 
Cost of shares redeemed   (2,625,065)   (1,201,543)    
Increase (Decrease) in net assets resulting from share transactions   35,599,216    (1,201,543)   2,202,041 
Total increase (decrease) in net assets   35,052,210    (1,084,542)   2,734,805 
Net Assets, beginning of period       5,853,803    3,118,998 
Net Assets, end of period†  $35,052,210   $4,769,261   $5,853,803 
† Including undistributed net investment income  $90,244   $14,819   $40,434 
                
** Shares of Common Stock Issued (no par value)               
Shares sold   1,450,001        100,000 
Shares redeemed   (100,001)   (50,000)    
Net increase (decrease)   1,350,000    (50,000)   100,000 

 

 
*Commencement of operations

 

See Notes to Financial Statements

19

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Morningstar International Moat ETF      
   For the Six
Months
Ended
March 31,
  For the Year
Ended September 30,
  For the Period
July 13, 2015 (a)
through
September 30,
      
   2018    2017      2016      2015        
   (unaudited)               
Net asset value, beginning of period    $35.49           $28.34     $26.48           $30.17               
Income from investment operations:                                          
Net investment income     0.30(b)     0.93(b)     0.76      0.18               
Net realized and unrealized gain (loss) on investments     0.35      6.59      1.33      (3.87)              
Total from investment operations     0.65      7.52      2.09      (3.69)              
Less:                                          
Dividends from net investment income     (0.98)     (0.37)     (0.23)                    
Distributions from net realized capital gains     (1.02)                                
Total dividends and distributions     (2.00)     (0.37)     (0.23)                    
Net asset value, end of period    $34.14     $35.49   $28.34   $26.48               
Total return (c)     1.87%(d)     26.91%     7.91%    (12.23)%(d)              
Ratios/Supplemental Data                                          
Net assets, end of period (000’s)  $102,422   $81,631   $12,755   $10,591               
Ratio of gross expenses to average net assets     0.68%(e)     0.84%     1.62%     2.49%(e)              
Ratio of net expenses to average net assets     0.57%(e)     0.56%     0.56%     0.56%(e)              
Ratio of net expenses to average net assets excluding interest expense     0.56%(e)     0.56%     0.56%     0.56%(e)              
Ratio of net investment income to average net assets     1.72%(e)     2.92%     2.99%     3.27%(e)              
Portfolio turnover rate (f)   53%(d)     129%     168%     54%(d)              
                                         
   Morningstar Wide Moat ETF  
   For the Six                                   
   Months Ended                                   
   March 31,  For the Year Ended September 30,  
   2018    2017     2016     2015     2014     2013 
   (unaudited)                                   
Net asset value, beginning of period         $40.33           $34.01        $27.96        $31.27        $27.09        $21.54 
Income from investment operations:                                          
Net investment income     0.34(b)     0.53(b)     0.48      0.57      0.37      0.23 
Net realized and unrealized gain (loss) on investments     1.22      6.20      6.19      (3.46)     4.04      5.46 
Total from investment operations     1.56      6.73      6.67      (2.89)     4.41      5.69 
Less:                                          
Dividends from net investment income     (0.46)     (0.41)     (0.62)     (0.42)     (0.23)     (0.14)
Net asset value, end of period    $41.43     $40.33   $34.01     $27.96     $31.27     $27.09 
Total return (c)     3.83%(d)     19.96%     24.23%     (9.41)%     16.35%     26.54%
Ratios/Supplemental Data                                          
Net assets, end of period (000’s)  $1,369,128   $1,286,451   $753,358   $742,364   $853,616   $364,395 
Ratio of gross expenses to average net assets     0.48%(e)     0.48%     0.50%     0.50%     0.50%     0.51%
Ratio of net expenses to average net assets     0.48%(e)     0.48%     0.49%     0.49%     0.49%     0.49%
Ratio of net expenses to average net assets excluding interest expense     0.48%(e)     0.48%     0.49%     0.49%     0.49%     0.49%
Ratio of net investment income to average net assets     1.61%(e)     1.42%     1.44%     1.88%     1.63%     1.48%
Portfolio turnover rate (f)     25%(d)     53%     178%     14%     15%     1%

 

 
(a) Commencement of operations
(b) Calculated based upon average shares outstanding
(c) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(d) Not Annualized
(e) Annualized
(f) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.

 

See Notes to Financial Statements

20

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   NDR CMG
Long/Flat
Allocation ETF
           
   For the Period
October 4,
2017 (a)
through
March 31,
2018
           
   (unaudited)           
Net asset value, beginning of period    $25.03                        
Income from investment operations:                              
Net investment income     0.23(b)                       
Net realized and unrealized gain on investments     0.80                        
Total from investment operations     1.03(h)                       
Less:                              
Dividends from net investment income     (0.10)                       
Net asset value, end of period    $25.96                        
Total return (c)     4.11%(d)                       
Ratios/Supplemental Data                              
Net assets, end of period (000’s)  $35,052                        
Ratio of gross expenses to average net assets (g)     1.21%(e)                       
Ratio of net expenses to average net assets (g)     0.55%(e)                       
Ratio of net expenses to average net assets excluding interest expense (g)     0.55%(e)                       
Ratio of net investment income to average net assets     1.84%(e)                       
Portfolio turnover rate (f)     7%(d)                       
                               
   Spin-Off ETF  
   For the Six
Months
Ended
March 31,
  For the Year
Ended September 30,
  For the Period
June 9, 2015 (a)
through
September 30,
 
   2018  2017  2016  2015  
   (unaudited)                       
Net asset value, beginning of period         $23.42             $20.79          $16.98             $19.78           
Income from investment operations:                              
Net investment income     0.14(b)     0.22(b)     0.39      0.05   
Net realized and unrealized gain (loss) on investments     0.51      2.73      3.53      (2.85)  
Total from investment operations     0.65      2.95      3.92      (2.80)  
Less:                              
Dividends from net investment income     (0.22)     (0.32)     (0.11)        
Net asset value, end of period    $23.85     $23.42     $20.79     $16.98   
Total return (c)     2.79%(d)     14.37%     23.22%    (14.16)%(d)  
Ratios/Supplemental Data                              
Net assets, end of period (000’s)  $4,769   $5,854   $3,119   $2,547   
Ratio of gross expenses to average net assets     2.48%(e)     2.66%     5.07%     6.24%(e)  
Ratio of net expenses to average net assets     0.55%(e)     0.55%     0.55%     0.55%(e)  
Ratio of net expenses to average net assets excluding interest expense     0.55%(e)     0.55%     0.55%     0.55%(e)  
Ratio of net investment income to average net assets     1.14%(e)     0.98%     2.13%     1.24%(e)  
Portfolio turnover rate (f)     22%(d)     53%     58%     30%(d)  

 

 
(a) Commencement of operations
(b) Calculated based upon average shares outstanding
(c) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(d) Not Annualized
(e) Annualized
(f) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(g) The ratios presented do not reflect the Fund’s proportionate share of income and expenses from the Fund’s investment in underlying funds.
(h) The amount shown for a share outstanding does not correspond with the aggregate net gain (loss) on investments for the period due to the timing and repurchase of shares in relation to fluctuating market values of the investments of the Fund.

 

See Notes to Financial Statements

21

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

March 31, 2018 (unaudited)

 

Note 1—Fund Organization—VanEck Vectors ETF Trust (the “Trust”) is registered under the Investment Company Act of 1940, as amended, as an open-end management investment company. The Trust was incorporated in Delaware as a statutory trust on March 15, 2001. The Trust operates as a series fund, and as of March 31, 2018, offers fifty-six investment portfolios, each of which represents a separate series of the Trust.

 

These financial statements relate only to the following investment portfolios: Morningstar International Moat ETF, Morningstar Wide Moat ETF, NDR CMG Long/Flat Allocation ETF, and Spin-Off ETF (formerly known as Global Spin-Off ETF), (each a “Fund” and, together, the “Funds”). Each Fund was created to provide investors with the opportunity to purchase a security representing a proportionate undivided interest in a portfolio of securities consisting of substantially all of the common stocks in substantially the same weighting, in an index sponsored, licensed or managed by Morningstar, Inc., Ned Davis Research, Inc. or Horizon Kinetics, LLC.

 

The Funds’ respective indices are presented below:

 

Fund   Index
Morningstar International Moat ETF   Morningstar® Global ex-US Moat Focus IndexSM(1)
Morningstar Wide Moat ETF   Morningstar® Wide Moat Focus IndexSM(1)
NDR CMG Long/Flat Allocation ETF   Ned Davis Research CMG US Large Cap Long/Flat Index(2)
Spin-Off ETF   Horizon Kinetics Global Spin-Off Index(3)

 

(1) Published by Morningstar, Inc.
(2) Published by Ned Davis Research, Inc.
(3) Published by Horizon Kinetics, LLC

 

Note 2—Significant Accounting Policies—The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.

 

The Funds are investment companies and are following accounting and reporting requirements of Accounting Standards Codification (“ASC”) 946 Financial Services—Investment Companies.

 

The following is a summary of significant accounting policies followed by the Funds.

 

A. Security Valuation—The Funds value their investments in securities and other assets and liabilities at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Securities traded on national exchanges or traded on the NASDAQ National Market System are valued at the last sales price as reported at the close of each business day. Securities traded on the NASDAQ Stock Market are valued at the NASDAQ official closing price. Over-the-counter securities not included in the NASDAQ National Market System and listed securities for which no sale was reported are valued at the mean of the bid and ask prices. To the extent these securities are actively traded they are categorized as Level 1 in the fair value hierarchy (described below). Certain foreign securities, whose values may be affected by market direction or events occurring before the Funds’ pricing time (4:00 p.m. Eastern Standard Time) but after the last close of the securities’ primary market, are fair valued using a pricing service and are categorized as Level 2 in the fair value hierarchy. The pricing service, using methods approved by the Board of Trustees, considers the correlation of the trading patterns of the foreign security to intraday trading in the U.S. markets, based on indices of domestic securities and other appropriate indicators such as prices of relevant ADR’s and futures contracts. The Funds may also fair value securities in other situations, such as, when a particular foreign market is closed but the Fund is open. Short-term obligations with sixty days or less to maturity are valued at amortized cost, which with accrued interest approximates fair value. Money market fund investments are valued at net asset value and are considered to be Level 1 in the fair value hierarchy. The Pricing Committee of the Van Eck Associate Corporation (the “Adviser”) provides oversight of the Funds’ valuation policies and procedures, which are approved by the Funds’ Board of Trustees. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities dealers, and other market sources to determine fair value. The Pricing Committee convenes regularly to review the fair value of financial instruments or other assets. If market quotations for a security or other asset are not readily available, or if the Adviser believes it does not otherwise reflect the fair value of a security or asset, the security or asset will be fair valued by the Pricing Committee in accordance with the Funds’ valuation policies and procedures. The Pricing Committee employs various methods for calibrating
22

 

 

  the valuation approaches utilized to determine fair value, including a regular review of key inputs and assumptions, periodic comparisons to valuations provided by other independent pricing services, transactional back-testing and disposition analysis.
   
  Certain factors such as economic conditions, political events, market trends, the nature of and duration of any restrictions on disposition, trading in similar securities of the issuer or comparable issuers and other security specific information are used to determine the fair value of these securities. Depending on the relative significance of valuation inputs, these securities may be classified either as Level 2 or Level 3 in the fair value hierarchy. The price which the Funds may realize upon sale of an investment may differ materially from the value presented in the Schedules of Investments.
   
  The Funds utilize various methods to measure the fair value of their investments on a recurring basis, which includes a hierarchy that prioritizes inputs to valuation methods used to measure fair value. The fair value hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The transfers between levels of the fair value hierarchy assume the financial instruments where transferred at the beginning of the reporting period. The three levels of the fair value hierarchy are described below:
   
  Level 1 — Quoted prices in active markets for identical securities.
   
  Level 2 — Significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
   
  Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
   
  A summary of the inputs, the levels used to value the Funds’ investments, and transfers between levels are located in the Schedules of Investments. Additionally, tables that reconcile the valuation of the Funds’ Level 3 investments and that present additional information about valuation methodologies and unobservable inputs, if applicable, are located in the Schedules of Investments.
   
B. Federal Income Taxes—It is each Fund’s policy to comply with the provisions of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Therefore, no federal income tax provision is required.
   
C. Dividends and Distributions to Shareholders—Dividends to shareholders from net investment income and distributions from net realized capital gains, if any, are declared and paid annually by each Fund. Income dividends and capital gain distributions are determined in accordance with U.S. income tax regulations, which may differ from such amounts determined in accordance with GAAP.
   
D. Currency Translation—Assets and liabilities denominated in foreign currencies and commitments under foreign currency contracts are translated into U.S. dollars at the closing prices of such currencies each business day as quoted by one or more sources. Purchases and sales of investments are translated at the exchange rates prevailing when such investments are acquired or sold. Foreign denominated income and expenses are translated at the exchange rates prevailing when accrued. The portion of realized and unrealized gains and losses on investments that result from fluctuations in foreign currency exchange rates is not separately disclosed in the financial statements. Recognized gains or losses attributable to foreign currency fluctuations on foreign currency denominated assets, other than investments, and liabilities are recorded as net realized gain (loss) on foreign currency transactions and foreign denominated assets and liabilities in the Statements of Operations.
   
E. Restricted Securities—The Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities, if any, is included at the end of each Fund’s Schedule of Investments.
23

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(unaudited) (continued)

 

F. Repurchase Agreements—The Funds may enter into repurchase agreements with financial institutions, deemed to be creditworthy by the Adviser, to generate income from their excess cash balances and to invest securities lending cash collateral. A repurchase agreement is an agreement under which a Fund acquires securities from a seller, subject to resale to the seller at an agreed upon price and date. A Fund, through its custodian/securities lending agent, takes possession of securities collateralizing the repurchase agreement. Pursuant to the terms of the repurchase agreement, such securities must have an aggregate market value greater than or equal to the terms of the repurchase price plus accrued interest at all times. If the value of the underlying securities falls below the value of the repurchase price plus accrued interest, the Funds will require the seller to deposit additional collateral by the next business day. If the request for additional collateral is not met, or the seller defaults on its repurchase obligation, the Funds maintain their right to sell the underlying securities at market value and may claim any resulting loss against the seller. Repurchase agreements held as of March 31, 2018 are reflected in the Schedules of Investments.
   
G. Offsetting Assets and Liabilities—In the ordinary course of business, the Funds enter into transactions subject to enforceable master netting or other similar agreements. Generally, the right of setoff in those agreements allows the Funds to set off any exposure to a specific counterparty with any collateral received or delivered to that counterparty based on the terms of the agreements. The Funds may pledge or receive cash and/or securities as collateral for derivative instruments, securities lending and repurchase agreements. For financial reporting purposes, the Funds present securities lending and repurchase agreement assets and liabilities on a gross basis in the Statements of Assets and Liabilities. Collateral held at March 31, 2018 is presented in the Schedules of Investments. Refer to related disclosures in Note 2G (Repurchase Agreements) and Note 9 (Securities Lending).
   
H. Other—Security transactions are accounted for on trade date. Realized gains and losses are determined based on the specific identification method. Dividend income is recorded on the ex-dividend date except that certain dividends from foreign securities are recognized upon notification of the ex-dividend date. Interest income, including amortization of premiums and discounts, is accrued as earned. The Funds may record distributions received in excess of income from certain underlying investments as a reduction of cost of investments and/or as an increase in capital gains. Such amounts are based on estimates if actual amounts are not available, and actual amounts of income, realized gains and return of capital may differ from estimated amounts.
   
  In the normal course of business, the Funds enter into contracts that contain a variety of general indemnifications. The Funds’ maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Funds that have not yet occurred. However, the Adviser believes the risk of loss under these arrangements to be remote.
   

Note 3—Investment Management and Other Agreements—The Adviser is the investment adviser to the Funds. The Adviser receives a management fee, calculated daily and payable monthly based on an annual rate of each Fund’s average daily net assets. The Adviser has agreed, until at least February 1, 2019, to waive management fees and assume expenses to prevent each Fund’s total annual operating expenses (excluding acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses) from exceeding expense limitations listed in the table below.

 

The current management fee rate, expense limitations and the amounts waived/assumed by the Adviser for the period ended March 31, 2018, are as follows:

 

   Management  Expense
Fund  Fee Rate  Limitations
Morningstar International Moat ETF        0.50%              0.56%     
Morningstar Wide Moat ETF   0.45    0.49 
NDR CMG Long/Flat Allocation ETF   0.50    0.55 
Spin-Off ETF   0.50    0.55 

 

Refer to Statements of Operations for the amounts waived/assumed by the Adviser.

 

In addition, Van Eck Securities Corporation, an affiliate of the Adviser, acts as the Funds’ distributor (“the Distributor”). Certain officers and a Trustee of the Trust are officers, directors or stockholders of the Adviser and Distributor.

24

 

 

Note 4—Investments—For the period ended March 31, 2018, the cost of purchases and proceeds from sales of investments other than U.S. government obligations and short-term obligations (excluding in-kind transactions described in Note 6) were as follows:

 

   Cost of Investments  Proceeds from
Fund  Purchased  Investments Sold
Morningstar International Moat ETF    $46,931,543        $49,463,193   
Morningstar Wide Moat ETF   333,849,947    340,697,462 
NDR CMG Long/Flat Allocation ETF   1,011,350    1,045,799 
Spin-Off ETF   1,171,925    1,204,489 

 

Note 5—Income Taxes—As of March 31, 2018, for Federal income tax purposes, the identified cost, gross unrealized appreciation, gross unrealized depreciation, and net unrealized appreciation(depreciation) of investments were as follows:

 

            Net Unrealized
      Gross Unrealized  Gross Unrealized  Appreciation
Fund  Cost of Investments  Appreciation  Depreciation  (Depreciation)
Morningstar International Moat ETF  $100,361,854   $5,542,331   $(3,264,725)  $2,277,606 
Morningstar Wide Moat ETF   1,378,827,110    95,133,703    (76,929,493)   18,204,210 
NDR CMG Long/Flat Allocation ETF   35,865,139        (777,741)   (777,741)
Spin-Off ETF   5,234,939    825,693    (352,387)   473,306 

 

The tax character of dividends paid to shareholders during the year ended September 30, 2017 was as follows:

 

   2017 Dividends
Fund  Ordinary Income
Morningstar International Moat ETF      $407,000    
Morningstar Wide Moat ETF   9,710,400 
Spin-Off ETF   48,600 

 

The tax character of current year distributions will be determined at the end of the current year.

 

At September 30, 2017, the tax character of current year distributions will be determined at the end of the current fiscal year. The Funds had capital loss carryforwards available to offset future capital gains, as follows:

 

   Post-Effective-  Post-Effective-   
   No Expiration  No Expiration   
   Short-Term  Long-Term   
Fund  Capital Losses  Capital Losses  Total
Morningstar Wide Moat ETF  $(102,440,499)  $(32,265,944)  $(134,706,443)
Spin-Off ETF   (58,333)       (58,333)

 

The Funds recognize the tax benefits of uncertain tax positions only where the position is “more-likely-than-not” to be sustained assuming examination by applicable tax authorities. Management has analyzed the Funds’ tax positions, and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on return filings for all open tax years. The Funds do not have exposure for additional years that might still be open in certain foreign jurisdictions. Therefore, no provision for income tax is required in the Funds’ financial statements. However, certain Funds are subject to foreign taxes on the appreciation in value of certain investments. The Funds provide for such taxes on both realized and unrealized appreciation.

 

The Funds recognize interest and penalties, if any, related to uncertain tax positions as income tax expense in the Statements of Operations. During the period ended March 31, 2018, the Funds did not incur any interest or penalties.

 

Note 6—Capital Share Transactions—As of March 31, 2018, there were an unlimited number of capital shares of beneficial interest authorized by the Trust with no par value. Fund shares are not individually redeemable and are issued and redeemed at their net asset value per share only through certain authorized broker-dealers (“Authorized Participants”) in blocks of shares (“Creation Units”), consisting of 50,000 shares, or multiples thereof.

 

The consideration for the purchase or redemption of Creation Units of the Funds generally consists of the in-kind contribution or distribution of securities constituting the Funds’ underlying index (“Deposit Securities”) plus a balancing cash component to equate the transaction to the net asset value per share of the Fund on the transaction date. Cash may also be substituted in an amount equivalent to the value of certain Deposit Securities, generally as a result of

25

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(unaudited) (continued)

 

market circumstances, or when the securities are not available in sufficient quantity for delivery or are not eligible for trading by the Authorized Participant. The Funds may issue Creation Units in advance of receipt of Deposit Securities subject to various conditions, including a requirement to maintain on deposit at the Custodian for the benefit of the Funds, collateral consisting of cash in the form of U.S. dollars at least equal to 115% of the daily marked to market value of the missing Deposit Securities.

 

Authorized Participants purchasing and redeeming Creation Units may pay transaction fees directly to The Bank of New York Mellon. In addition, the Funds may impose certain variable fees for creations and redemptions with respect to transactions in Creation Units for cash, or on transactions effected outside the clearing process, which are treated as increases in capital. These variable fees, if any, are reflected in share transactions in the Statements of Changes in Net Assets.

 

For the period ended March 31, 2018, the Funds had in-kind contributions and redemptions as follows:

 

Fund  In-Kind Contributions  In-Kind Redemptions
Morningstar International Moat ETF          $33,798,551               $10,160,351       
Morningstar Wide Moat ETF   341,731,226    288,821,782 
NDR CMG Long/Flat Allocation ETF   38,223,925    2,624,973 
Spin-Off ETF       1,201,058 

 

The in-kind contributions and in-kind redemptions in this table represent the accumulation of each Fund’s daily net shareholder transactions including rebalancing activity, while the Statements of Changes in Net Assets reflect shareholder transactions including any cash component of the transactions.

 

Note 7—Concentration of Risk—The investment objective of each Fund is to seek investment results that correspond generally to the price and yield performance, before fees and expenses, of its underlying index, as indicated in the name of each Fund. The Adviser uses a “passive” or index approach to achieve each Fund’s investment objective by investing in a portfolio of securities that generally replicates the Funds’ index. Each of the Fund is classified as a non-diversified fund under the 1940 Act. Non-diversified funds generally hold securities of fewer issuers than diversified funds and may be more susceptible to the risks associated with these particular issuers, or to a single economic, political or regulatory occurrence affecting these issuers. The Funds may purchase securities on foreign exchanges. Securities of foreign issuers involve special risks and considerations not typically associated with investing in U.S. issuers. These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.

 

NDR CMG Long/Flat Allocation ETF may invest in shares of other funds, including ETFs that track the S&P 500 Index. As a result, the Fund will indirectly be exposed to the risks of an investment in the underlying funds. Shares of other funds have many of the same risks as direct investments in common stocks or bonds. In addition, the market value of the Fund’s shares is expected to rise and fall as the value of the underlying index or bond rises and falls. The market value of such funds’ shares may differ from the net asset value of the particular fund.

 

Spin-Off ETF may invest in companies that have been spun-off from a parent company for a number of reasons, including but not limited to low growth prospects, high capital requirements or an unfavorable capitalization structure. Investments in spun-off companies are subject to the risk that any of these characteristics will adversely affect the value of investments in the spun-off companies. There can be no assurance that a spun-off company will be financially independent or profitable, especially where the company represented a non-core or non-competitive business line of the parent company at the time of the spin-off.

 

Spin-Off ETF may invest directly in real estate investment trusts (“REITs”) and is exposed to the risk of owning real estate directly, as well as to risks that relate specifically to the way in which REITs are organized and operated. REITs generally invest directly in real estate, in mortgages or in some combination of the two. The Fund indirectly bears management expenses along with the direct expenses of the Fund. Individual REITs may own a limited number of properties and may concentrate in a particular region or property type. REITs may also be subject to heavy cash flow dependency, default by borrowers and self-liquidation.

26

 

 

In March 2017, the United Kingdom triggered Article 50, and is now scheduled to leave the European Union (“EU”) by the end of March 2019. Significant uncertainty exists on how the withdrawal will take place, the terms of the withdrawal and the effects such withdrawal will have on the EU and the United Kingdom. This may further impact the value of the Euro and the British pound sterling, and has caused volatility and uncertainty in European and global markets

 

As a result of events involving Ukraine and the Russian Federation, the United States and the European Union have imposed sanctions on certain Russian individuals and companies. These sanctions do not currently impact the Funds. Additional economic sanctions may be imposed or other actions may be taken that may adversely affect the value and liquidity of the Russian-related issuers held by the Funds.

 

A more complete description of risks is included in each Fund’s Prospectus and Statement of Additional Information.

 

Note 8—Trustee Deferred Compensation Plan—The Trust has a Deferred Compensation Plan (the “Plan”) for Trustees under which the Trustees can elect to defer receipt of their trustee fees until retirement, disability or termination from the Board of Trustees. The fees otherwise payable to the participating Trustees are deemed invested in shares of the Funds as directed by the Trustees.

 

The expense for the Plan is included in “Trustees’ fees and expenses” in the Statements of Operations. The liability for the Plan is shown as “Deferred Trustee fees” in the Statements of Assets and Liabilities.

 

Note 9—Securities Lending—To generate additional income, each of the Funds may lend its securities pursuant to a securities lending agreement with The Bank of New York Mellon, the securities lending agent and also the Funds’ custodian. Each Fund may lend up to 33% of its investments requiring that the loan be continuously collateralized by cash, U.S. government or U.S. government agency securities, shares of an investment trust or mutual fund, or any combination of cash and such securities at all times equal to at least 102% (105% for foreign securities) of the market value plus accrued interest on the securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled on the next business day. During the term of the loan, the Funds will continue to receive any dividends, interest or amounts equivalent thereto on the securities loaned, while receiving a fee from the borrower and/or earning interest on the investment of the cash collateral. Such fees and interest are shared with the securities lending agent under the terms of the securities lending agreement. The Funds may pay reasonable finders’, administrative and custodial fees in connection with a loan of its securities. Securities lending income is disclosed as such in the Statements of Operations. The collateral for securities loaned is recognized in the Schedules of Investments and the Statements of Assets and Liabilities. The cash collateral is maintained on the Funds’ behalf by the lending agent and is invested in repurchase agreements collateralized by obligations of the U.S. Treasury and/or Government Agencies. Loans are subject to termination at the option of the borrower or the Funds. Upon termination of the loan, the borrower will return to the lender securities identical to the securities loaned. The Funds bear the risk of delay in recovery of, or even loss of rights in, the securities loaned should the borrower of the securities fail financially. The value of loaned securities and related collateral outstanding at March 31, 2018 are presented on a gross basis in the Schedules of Investments and Statements of Assets and Liabilities.

 

The following table presents repurchase agreements held as collateral by type of security on loan as of March 31, 2018:

 

   Gross Amount of Recognized
   Liabilities for Securities Loaned
   in the Statements of Assets
   and Liabilities*
Fund  Equity Securities
Morningstar Wide Moat ETF  $31,824,681 
Spin-Off ETF   909,458 

 

*Remaining contractual maturity of the agreements: overnight and continuous
27

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(unaudited) (continued)

 

Note 10—Bank Line of Credit—The Funds may participate in a $200 million committed credit facility (the “Facility”) to be utilized for temporary financing until the settlement of sales or purchases of portfolio securities, the repurchase or redemption of shares of the Funds and other temporary or emergency purposes. The Funds have agreed to pay commitment fees, pro rata, based on the unused but available balance. Interest is charged to the Funds at rates based on prevailing market rates in effect at the time of borrowings. During the year ended March 31, 2018, the following Funds borrowed under this Facility:

 

            Outstanding Loan
   Days  Average Daily  Average  Balance as of
Fund  Outstanding  Loan Balance  Interest Rate  March 31, 2018
Morningstar International Moat ETF       87          $369,954    2.73%      $635,888    
Morningstar Wide Moat ETF   145    1,942,211    2.68     

 

Note 11—Custodian Fees—The Funds have entered into an expense offset agreement with the custodian wherein they receive a credit toward the reduction of custodian fees whenever there are uninvested cash balances. The Funds could have invested their cash balances elsewhere if they had not agreed to a reduction in fees under the expense offset agreement with the custodian. For the period ended March 31, 2018, there were offsets to custodian fees and these amounts are reflected in custody expense in the Statements of Operations.

 

Note 12—Subsequent Event Review—The Funds have evaluated subsequent events and transactions for potential recognition or disclosure through the date the financial statements were issued.

28

VANECK VECTORS ETF TRUST

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENT

March 31, 2018 (unaudited)

 

At a meeting held on September 7, 2017 (the “Meeting”), the Board of Trustees (the “Board”) of VanEck Vectors® ETF Trust (the “Trust”), including all of the Trustees that are not interested persons of the Trust (the “Independent Trustees”), considered and approved an investment management agreement between the Trust and Van Eck Associates Corporation (the “Adviser”) (the “Investment Management Agreement”) with respect to the VanEck Vectors Real Asset Allocation ETF (the “Fund”).

 

The Board’s approval of the Investment Management Agreement was based on a comprehensive consideration of all of the information available to the Trustees and was not the result of any single factor. Some of the factors that figured particularly in the Trustees’ deliberations and how the Trustees considered those factors are described below, although individual Trustees may have evaluated the information presented differently, giving different weights to various factors.

 

In advance of the Meeting, the Trustees received materials from the Adviser, including expense information for other funds. The Adviser provided the Trustees with information regarding, among other things, the various aspects of the Fund’s proposed investment program, fee arrangements and service provider arrangements. The Independent Trustees’ consideration of the Investment Management Agreement was based, in part, on their review of information obtained through discussions with the Adviser at the Meeting regarding the management of the Fund, information obtained at other meetings of the Trustees and/or based on their review of the materials provided by the Adviser, including the background and experience of the portfolio managers and others proposed to be involved in the management and administration of the Fund. The Trustees considered the terms and scope of services that the Adviser would provide under the Investment Management Agreement, including the Adviser’s commitment to waive certain fees and/or pay expenses of the Fund to the extent necessary to prevent the operating expenses of the Fund from exceeding agreed upon limits for a period of at least one year following the effective date of their respective registration statements.

 

The Trustees considered the benefits, other than the fees under the Investment Management Agreement, that the Adviser would receive from serving as adviser to the Fund. The Trustees did not consider historical information about the cost of the services provided by the Adviser or the profitability of the Fund to the Adviser because the Fund had not yet commenced operations. In addition, because the Fund had not yet commenced operations, the Trustees could not consider the historical performance or the quality of services previously provided to the Fund by the Adviser, although they concluded that the nature, quality, and extent of the services to be provided by the Adviser were appropriate based on the Trustees’ knowledge of the Adviser and its personnel and the operations of the other series of the Trust.

 

The Independent Trustees were advised by and met in executive session with their independent counsel at the Meeting as part of their consideration of the Investment Management Agreement.

 

In voting to approve the Investment Management Agreement, the Trustees, including the Independent Trustees, concluded that the terms of the Investment Management Agreement are reasonable and fair in light of the services to be performed, expenses to be incurred and such other matters as the Trustees considered relevant in the exercise of their reasonable judgment. The Trustees further concluded that the Investment Management Agreement is in the best interest of the Fund and the Fund’s shareholders.

29

 

This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by a VanEck Vectors ETF Trust (the “Trust”) Prospectus, which includes more complete information. An investor should consider the investment objective, risks, and charges and expenses of the Funds carefully before investing. The prospectus contains this and other information about the investment company. Please read the prospectus carefully before investing.

 

Additional information about the Trust’s Board of Trustees/Officers and a description of the policies and procedures the Trust uses to determine how to vote proxies relating to portfolio securities are provided in the Statement of Additional Information. The Statement of Additional Information and information regarding how the Trust voted proxies relating to portfolio securities during the most recent twelve month period ending June 30 is available, without charge, by calling 800.826.2333, or by visiting vaneck.com, or on the Securities and Exchange Commission’s website at http://www.sec.gov.

 

The Trust files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Trust’s Form N-Qs are available on the Commission’s website at http://www.sec.gov and may be reviewed and copied at the Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 202.942.8090. The Funds’ complete schedules of portfolio holdings are also available by calling 800.826.2333 or by visiting vaneck.com.

 

 

 

Investment Adviser: Van Eck Associates Corporation  
Distributor: Van Eck Securities Corporation  
  666 Third Avenue, New York, NY 10017  
  vaneck.com  
Account Assistance: 800.826.2333 STRATSAR

Item 2. CODE OF ETHICS.

  Not applicable.

Item 3. AUDIT COMMITTEE FINANCIAL EXPERT.

  Not applicable.

Item 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

  Not applicable.


Item 5. AUDIT COMMITTEE OF LISTED REGISTRANTS.

     Not applicable.

Item 6. SCHEDULE OF INVESTMENTS.

     Information included in Item 1.

Item 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END
        MANAGEMENT INVESTMENT COMPANIES.

     Not applicable.

Item 8. PORTFOLIO MANAGER OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES.

     Not applicable.

Item 9. PURCHASE OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT
        COMPANY AND AFFILIATED PURCHASERS.

     Not applicable.

Item 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

     Not applicable.

Item 11. CONTROLS AND PROCEDURES.

(a)  The registrant's principal executive and principal financial officers, or
     persons performing similar functions, have concluded that the registrant's
     disclosure controls and procedures (as defined in Rule 30a-3(c) under the
     Investment Company Act of 1940, as amended (the "1940 Act") (17 CFR
     270.30a-3(c)) are effective, as of a date within 90 days of the filing
     date of the report that includes the disclosure required by this paragraph,
     based on their evaluation of these controls and procedures required
     by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules
     13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934,
     as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).

(b)  There were no changes in the registrant's internal control over financial
     reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR
     270.30a-3(d)) that occurred during the period covered by this report that has
     materially affected, or is reasonably likely to materially affect, the registrant's
     internal control over financial reporting.

Item 12. DISCLOSURE OF SECURITIES LENDING ACTIVITIES FOR CLOSED-END MANAGEMENT COMPANIES.

     Not applicable.

Item 13. EXHIBITS.

(a)(1) Not applicable.

(a)(2) A separate certification for each principal executive officer and
       principal financial officer of the registrant as required by Rule 30a-2(a)
       under the Act (17 CFR 270.30a-2(a)) is attached as Exhibit 99.CERT.

(b)  Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 is
     furnished as Exhibit 99.906CERT.
 


                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934 and the
Investment Company Act of 1940, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) VANECK VECTORS ETF TRUST

By (Signature and Title) /s/ John J. Crimmins, Treasurer & Chief Financial Officer
                         ---------------------------------------------------------
Date June 8, 2018
     ---------------

Pursuant to the requirements of the Securities Exchange Act of 1934 and the
Investment Company Act of 1940, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.

By (Signature and Title) /s/ Jan F. van Eck, Chief Executive Officer
                        --------------------------------------------
Date June 8, 2018
     ---------------

By (Signature and Title)  /s/ John J. Crimmins, Treasurer & Chief Financial Officer
                        -----------------------------------------------------------

Date June 8, 2018
     ---------------